{"id":"linezolid","rwe":[{"pmid":"41901773","year":"2026","title":"Whole-Genome Sequencing and Phenotypic Drug Susceptibility Testing of Bedaquilin, Delamanid, Pretomanid, and Linezolid in Drug-Resistant Mycobacterium tuberculosis from a Single Institute in South Korea.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41901277","year":"2026","title":"Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41894901","year":"2026","title":"Linezolid-associated adverse events and outcomes in the treatment of multidrug/rifampicin-resistant tuberculosis: A systematic review and meta-analysis of randomized controlled trials.","finding":"","journal":"Journal of infection and public health","studyType":"Clinical Study"},{"pmid":"41894629","year":"2026","title":"Investigation of In vitro Efficacy of New Generation Drugs Tedizolid and Omadacycline against Nontuberculous Mycobacteria.","finding":"","journal":"International journal of mycobacteriology","studyType":"Clinical Study"},{"pmid":"41894624","year":"2026","title":"Prevalence of Bedaquiline Resistance among Drug Resistant - Tuberculosis Cases at a Tertiary Healthcare Setting in Metropolitan City of Maharashtra, India.","finding":"","journal":"International journal of mycobacteriology","studyType":"Clinical Study"}],"_fda":{"id":"ea8ff456-80d5-4f40-b397-a25b31a77947","set_id":"16007ca5-7956-4414-af38-406a6623400e","openfda":{"nui":["N0000175495","M0361132"],"unii":["ISQ9I6J12J"],"route":["ORAL"],"rxcui":["311345"],"spl_id":["ea8ff456-80d5-4f40-b397-a25b31a77947"],"brand_name":["Linezolid"],"spl_set_id":["16007ca5-7956-4414-af38-406a6623400e"],"package_ndc":["0054-0319-50"],"product_ndc":["0054-0319"],"generic_name":["LINEZOLID"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Oxazolidinones [CS]"],"substance_name":["LINEZOLID"],"pharm_class_epc":["Oxazolidinone Antibacterial [EPC]"],"manufacturer_name":["Hikma Pharmaceuticals USA Inc."],"application_number":["ANDA200068"],"is_original_packager":[true]},"version":"16","pregnancy":["8.1 Pregnancy Risk Summary Available data from published and postmarketing case reports with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. When administered during organogenesis, linezolid did not cause malformations in mice, rats, or rabbits at maternal exposure levels approximately 6.5 times (mice), equivalent to (rats), or 0.06 times (rabbits) the clinical therapeutic exposure, based on AUCs. However, embryo-fetal lethality was observed in mice at 6.5 times the estimated human exposure. When female rats were dosed during organogenesis through lactation, postnatal survival of pups was decreased at doses approximately equivalent to the estimated human exposure based on AUCs ( see Data ) . The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data : In mice, embryo-fetal toxicities were observed only at doses that caused maternal toxicity (clinical signs and reduced body weight gain). An oral dose of 450 mg/kg/day given from Gestation Day (GD) 6-16 (6.5 times the estimated human exposure based on AUCs) correlated with increased postimplantational embryo death, including total litter loss, decreased fetal body weights, and an increased incidence of costal cartilage fusion. Neither maternal nor embryo-fetal toxicities were observed at doses up to 150 mg/kg/day. Fetal malformations were not observed. In rats, fetal toxicity was observed at 15 and 50 mg/kg/day administered orally from GD 6-17 (exposures 0.22 times to approximately equivalent to the estimated human exposure, respectively, based on AUCs). The effects consisted of decreased fetal body weights and reduced ossification of sternebrae, a finding often seen in association with decreased fetal body weights. Fetal malformations were not observed. Maternal toxicity, in the form of reduced body weight gain, was seen at 50 mg/kg/day. In rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) when administered at an oral dose of 15 mg/kg/day given from GD 6-20 (0.06 times the estimated human exposure based on AUCs). Fetal malformations were not observed. When female rats were treated with 50 mg/kg/day (approximately equivalent to the estimated human exposure based on AUCs) of linezolid during pregnancy and lactation, (GD 6 through Lactation Day 20), survival of pups was decreased on postnatal days 1 to 4. Male and female pups permitted to mature to reproductive age, when mated, showed an increase in preimplantation loss."],"overdosage":["10 OVERDOSAGE In the event of overdosage, supportive care is advised, with maintenance of glomerular filtration. Hemodialysis may facilitate more rapid elimination of linezolid. In a Phase 1 clinical trial, approximately 30% of a dose of linezolid was removed during a 3-hour hemodialysis session beginning 3 hours after the dose of linezolid was administered. Data are not available for removal of linezolid with peritoneal dialysis or hemoperfusion. Clinical signs of acute toxicity in animals were decreased activity and ataxia in rats and vomiting and tremors in dogs treated with 3,000 mg/kg/day and 2,000 mg/kg/day, respectively."],"description":["11 DESCRIPTION Linezolid for Oral Suspension contains linezolid, which is a synthetic antibacterial agent of the oxazolidinone class. The chemical name for linezolid is N-[[(S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-ox- azolidinyl]methyl] acetamide. The molecular formula is C 16 H 20 FN 3 O 4 . Its molecular weight is 337.35, and its chemical structure is represented below: Linezolid for Oral Suspension is supplied as an orange-flavored powder for constitution into a suspension for oral administration. Following constitution, each 5 mL contains 100 mg of linezolid. Inactive ingredients are aspartame, carboxymethylcellulose sodium, citric acid (anhydrous), colloidal silicon dioxide, hypromellose, mannitol, microcrystalline cellulose, natural orange flavor, sodium benzoate, sodium chloride, sodium citrate, sucrose, and xanthan gum [see Patient Counseling Information ( 17 )]. The sodium (Na + ) content is 8.52 mg per 5 mL (0.4 mEq per 5 mL). chem-structure.jpg"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.3 Oral Suspension Linezolid for Oral Suspension Supplied as a dry, white to tan, orange-flavored powder. When constituted as directed, each bottle will contain 150 mL of a suspension providing the equivalent of 100 mg of linezolid per each 5 mL. NDC 0054-0319-50: 150 mL per Bottle (when constituted) 16.4 Storage and Handling Store at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.] Keep bottles tightly closed. Protect from light and moisture."],"microbiology":["12.4 Microbiology Mechanism of Action Linezolid is a synthetic antibacterial agent of the oxazolidinone class, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is essential for bacterial reproduction. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci . For streptococci , linezolid was found to be bactericidal for the majority of isolates. Resistance In vitro studies have shown that point mutations in the 23S rRNA are associated with linezolid resistance. Reports of vancomycin-resistant Enterococcus faecium becoming resistant to linezolid during its clinical use have been published. There are reports of Staphylococcus aureus (methicillin-resistant) developing resistance to linezolid during clinical use. The linezolid resistance in these organisms is associated with a point mutation in the 23S rRNA (substitution of thymine for guanine at position 2576) of the organism. Organisms resistant to oxazolidinones via mutations in chromosomal genes encoding 23S rRNA or ribosomal proteins (L3 and L4) are generally cross-resistant to linezolid. Also linezolid resistance in staphylococci mediated by the enzyme methyltransferase has been reported. This resistance is mediated by the cfr (chloramphenicol-florfenicol) gene located on a plasmid which is transferable between staphylococci . Interaction with Other Antimicrobial Drugs In vitro studies have demonstrated additivity or indifference between linezolid and vancomycin, gentamicin, rifampin, imipenem-cilastatin, aztreonam, ampicillin, or streptomycin. Linezolid has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage ( 1 )]. Gram-positive bacteria Enterococcus faecium (vancomycin-resistant isolates only) Staphylococcus aureus (including methicillin-resistant isolates) Streptococcus agalactiae Streptococcus pneumoniae Streptococcus pyogenes The following in vitro data are available, but their clinical significance is unknown. Greater than 90% of the following bacteria exhibit an in vitro MIC less than or equal to the linezolid-susceptible breakpoint for organisms of similar genus. The safety and effectiveness of linezolid in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials. Gram-positive bacteria Enterococcus faecalis (including vancomycin-resistant isolates) Enterococcus faecium (vancomycin-susceptible isolates) Staphylococcus epidermidis (including methicillin-resistant isolates) Staphylococcus haemolyticus Viridans group streptococci Gram-negative bacteria Pasteurella multocida Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"geriatric_use":["8.5 Geriatric Use Of the 2,046 patients treated with linezolid in Phase 3 comparator-controlled clinical trials, 589 (29%) were 65 years or older and 253 (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of linezolid for the treatment of pediatric patients with the following infections are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from a comparator-controlled study of Gram-positive infections in pediatric patients ranging in age from birth through 11 years [see Indications and Usage ( 1 ), Clinical Pharmacology ( 12.3 ) and Clinical Studies ( 14 )]: • nosocomial pneumonia • complicated skin and skin structure infections • community-acquired pneumonia (also supported by evidence from an uncontrolled study in patients ranging in age from 8 months through 12 years) • vancomycin-resistant Enterococcus faecium infections The safety and effectiveness of linezolid for the treatment of pediatric patients with the following infection have been established in a comparator-controlled study in pediatric patients ranging in age from 5 through 17 years [see Clinical Studies ( 14 )]: • uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes Pharmacokinetic information generated in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) linezolid concentrations following single and multiple dosing of linezolid; therapeutic concentrations were not consistently achieved or maintained in the CSF. Therefore, the use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended. The pharmacokinetics of linezolid have been evaluated in pediatric patients from birth to 17 years of age. In general, weight-based clearance of linezolid gradually decreases with increasing age of pediatric patients. However, in preterm (gestational age < 34 weeks) neonates < 7 days of age, linezolid clearance is often lower than in full-term neonates < 7 days of age. Consequently, preterm neonates < 7 days of age may need an alternative linezolid dosing regimen of 10 mg/kg every 12 hours [see Dosage and Administration ( 2.1 ) and Clinical Pharmacology ( 12.3 )]. In limited clinical experience, 5 out of 6 (83%) pediatric patients with infections due to Gram-positive pathogens with minimum inhibitory concentrations (MICs) of 4 mcg/mL treated with linezolid had clinical cures. However, pediatric patients exhibit wider variability in linezolid clearance and systemic exposure (AUC) compared with adults. In pediatric patients with a sub-optimal clinical response, particularly those with pathogens with MIC of 4 mcg/mL, lower systemic exposure, site and severity of infection, and the underlying medical condition should be considered when assessing clinical response [see Clinical Pharmacology ( 12.3 ) and Dosage and Administration ( 2 )]."],"effective_time":"20250130","clinical_studies":["14 CLINICAL STUDIES 14.1 Adults Nosocomial Pneumonia : Adult patients with clinically and radiologically documented nosocomial pneumonia were enrolled in a randomized, multi-center, double-blind trial. Patients were treated for 7 to 21 days. One group received linezolid I.V. injection 600 mg every 12 hours, and the other group received vancomycin 1 g every 12 hours intravenously. Both groups received concomitant aztreonam (1 to 2 g every 8 hours intravenously), which could be continued if clinically indicated. There were 203 linezolid-treated and 193 vancomycin-treated patients enrolled in the study. One hundred twenty-two (60%) linezolid-treated patients and 103 (53%) vancomycin-treated patients were clinically evaluable. The cure rates in clinically evaluable patients were 57% for linezolid-treated patients and 60% for vancomycin‑treated patients. The cure rates in clinically evaluable patients with ventilator-associated pneumonia were 47% for linezolid-treated patients and 40% for vancomycin-treated patients. A modified intent-to-treat (MITT) analysis of 94 linezolid-treated patients and 83 vancomycin-treated patients included subjects who had a pathogen isolated before treatment. The cure rates in the MITT analysis were 57% in linezolid-treated patients and 46% in vancomycin‑treated patients. The cure rates by pathogen for microbiologically evaluable patients are presented in Table 12. Table 12. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with Nosocomial Pneumonia Cured Pathogen Linezolid n/N (%) Vancomycin n/N (%) Staphylococcus aureus 23/38 (61) 14/23 (61) Methicillin-resistant S. aureus 13/22 (59) 7/10 (70) Streptococcus pneumoniae 9/9 (100) 9/10 (90) Complicated Skin and Skin Structure Infections Adult patients with clinically documented complicated skin and skin structure infections were enrolled in a randomized, multi-center, double-blind, double-dummy trial comparing study medications administered intravenously followed by medications given orally for a total of 10 to 21 days of treatment. One group of patients received linezolid I.V. Injection 600 mg every 12 hours followed by linezolid tablets 600 mg every 12 hours; the other group received oxacillin 2 g every 6 hours intravenously followed by dicloxacillin 500 mg every 6 hours orally. Patients could receive concomitant aztreonam if clinically indicated. There were 400 linezolid-treated and 419 oxacillin-treated patients enrolled in the study. Two hundred forty-five (61%) linezolid-treated patients and 242 (58%) oxacillin-treated patients were clinically evaluable. The cure rates in clinically evaluable patients were 90% in linezolid-treated patients and 85% in oxacillin-treated patients. A modified intent-to-treat (MITT) analysis of 316 linezolid-treated patients and 313 oxacillin-treated patients included subjects who met all criteria for study entry. The cure rates in the MITT analysis were 86% in linezolid-treated patients and 82% in oxacillin-treated patients. The cure rates by pathogen for microbiologically evaluable patients are presented in Table 13. Table 13. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with Complicated Skin and Skin Structure Infections Pathogen Cured Linezolid n/N (%) Oxacillin/Dicloxacillin n/N (%) Staphylococcus aureus 73/83 (88) 72/84 (86) Methicillin-resistant S. aureus 2/3 (67) 0/0 (-) Streptococcus agalactiae 6/6 (100) 3/6 (50) Streptococcus pyogenes 18/26 (69) 21/28 (75) A separate study provided additional experience with the use of linezolid in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. This was a randomized, open-label trial in hospitalized adult patients with documented or suspected MRSA infection. One group of patients received linezolid I.V. injection 600 mg every 12 hours followed by linezolid tablets 600 mg every 12 hours. The other group of patients received vancomycin 1 g every 12 hours intravenously. Both groups were treated for 7 to 28 days, and could receive concomitant aztreonam or gentamicin if clinically indicated. The cure rates in microbiologically evaluable patients with MRSA skin and skin structure infection were 26/33 (79%) for linezolid-treated patients and 24/33 (73%) for vancomycin-treated patients. Diabetic Foot Infections : Adult diabetic patients with clinically documented complicated skin and skin structure infections (“diabetic foot infections”) were enrolled in a randomized (2:1 ratio), multi-center, open-label trial comparing study medications administered intravenously or orally for a total of 14 to 28 days of treatment. One group of patients received linezolid 600 mg every 12 hours intravenously or orally; the other group received ampicillin/sulbactam 1.5 to 3 g intravenously or amoxicillin/clavulanate 500 to 875 mg every 8 to 12 hours orally. In countries where ampicillin/sulbactam is not marketed, amoxicillin/clavulanate 500 mg to 2 g every 6 hours was used for the intravenous regimen. Patients in the comparator group could also be treated with vancomycin 1 g every 12 hours intravenously if MRSA was isolated from the foot infection. Patients in either treatment group who had Gram-negative bacilli isolated from the infection site could also receive aztreonam 1 to 2 g every 8-12 hours intravenously. All patients were eligible to receive appropriate adjunctive treatment methods, such as debridement and off-loading, as typically required in the treatment of diabetic foot infections, and most patients received these treatments. There were 241 linezolid-treated and 120 comparator-treated patients in the intent-to-treat (ITT) study population. Two hundred twelve (86%) linezolid-treated patients and 105 (85%) comparator-treated patients were clinically evaluable. In the ITT population, the cure rates were 68.5% (165/241) in linezolid-treated patients and 64% (77/120) in comparator-treated patients, where those with indeterminate and missing outcomes were considered failures. The cure rates in the clinically evaluable patients (excluding those with indeterminate and missing outcomes) were 83% (159/192) and 73% (74/101) in the linezolid- and comparator-treated patients, respectively. A critical post-hoc analysis focused on 121 linezolid-treated and 60 comparator-treated patients who had a Gram-positive pathogen isolated from the site of infection or from blood, who had less evidence of underlying osteomyelitis than the overall study population, and who did not receive prohibited antimicrobials. Based upon that analysis, the cure rates were 71% (86/121) in the linezolid-treated patients and 63% (38/60) in the comparator-treated patients. None of the above analyses were adjusted for the use of adjunctive therapies. The cure rates by pathogen for microbiologically evaluable patients are presented in Table 14. Table 14. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with Diabetic Foot Infections Pathogen Cured Linezolid n/N (%) Comparator n/N (%) Staphylococcus aureus 49/63 (78) 20/29 (69) Methicillin-resistant S. aureus 12/17 (71) 2/3 (67) Streptococcus agalactiae 25/29 (86) 9/16 (56) Vancomycin-Resistant Enterococcal Infections : Adult patients with documented or suspected vancomycin-resistant enterococcal infection were enrolled in a randomized, multi-center, double-blind trial comparing a high dose of linezolid (600 mg) with a low dose of linezolid (200 mg) given every 12 hours either intravenously (IV) or orally for 7 to 28 days. Patients could receive concomitant aztreonam or aminoglycosides. There were 79 patients randomized to high-dose linezolid and 66 to low-dose linezolid. The intent-to-treat (ITT) population with documented vancomycin-resistant enterococcal infection at baseline consisted of 65 patients in the high-dose arm and 52 in the low-dose arm. The cure rates for the ITT population with documented vancomycin-resistant enterococcal infection at baseline are presented in Table 15 by source of infection. These cure rates do not include patients with missing or indeterminate outcomes. The cure rate was higher in the high-dose arm than in the low-dose arm, although the difference was not statistically significant at the 0.05 level. Table 15. Cure Rates at the Test-of-Cure Visit for ITT Adult Patients with Documented Vancomycin-Resistant Enterococcal Infections at Baseline Cured Source of Infection Linezolid 600 mg every 12 hours n/N (%) Linezolid 200 mg every 12 hours n/N (%) Any site 39/58 (67) 24/46 (52) Any site with associated bacteremia 10/17 (59) 4/14 (29) Bacteremia of unknown origin 5/10 (50) 2/7 (29) Skin and skin structure 9/13 (69) 5/5 (100) Urinary tract 12/19 (63) 12/20 (60) Pneumonia 2/3 (67) 0/1 (0) Other Includes sources of infection such as hepatic abscess, biliary sepsis, necrotic gall bladder, pericolonic abscess, pancreatitis, and catheter-related infection. 11/13 (85) 5/13 (39) 14.2 Pediatric Patients Infections due to Gram-positive Bacteria : A safety and efficacy study provided experience on the use of linezolid in pediatric patients for the treatment of nosocomial pneumonia, complicated skin and skin structure infections, and other infections due to Gram-positive bacterial pathogens, including methicillin-resistant and -susceptible Staphylococcus aureus and vancomycin-resistant Enterococcus faecium . Pediatric patients ranging in age from birth through 11 years with infections caused by the documented or suspected Gram-positive bacteria were enrolled in a randomized, open-label, comparator-controlled trial. One group of patients received linezolid I.V. Injection 10 mg/kg every 8 hours followed by Linezolid for Oral Suspension 10 mg/kg every 8 hours. A second group received vancomycin 10 to 15 mg/kg intravenously every 6 to 24 hours, depending on age and renal clearance. Patients who had confirmed VRE infections were placed in a third arm of the study and received linezolid 10 mg/kg every 8 hours intravenously and/or orally. All patients were treated for a total of 10 to 28 days and could receive concomitant Gram-negative antibacterial drugs if clinically indicated. In the intent-to-treat (ITT) population, there were 206 patients randomized to linezolid and 102 patients randomized to vancomycin. The cure rates for ITT, MITT, and clinically evaluable patients are presented in Table 16. After the study was completed, 13 additional patients ranging from 4 days through 16 years of age were enrolled in an open-label extension of the VRE arm of the study. Table 17 provides clinical cure rates by pathogen for microbiologically evaluable patients including microbiologically evaluable patients with vancomycin-resistant Enterococcus faecium from the extension of this study. Table 16. Cure Rates at the Test-of-Cure Visit for Intent-to-Treat, Modified Intent-to-Treat, and Clinically Evaluable Pediatric Patients for the Overall Population and by Select Baseline Diagnosis Population ITT MITT MIT = ITT patients with an isolated Gram-positive pathogen at baseline Clinically Evaluable Linezolid n/N (%) Vancomycin n/N (%) Linezolid n/N (%) Vancomycin n/N (%) Linezolid n/N (%) Vancomycin n/N (%) Any diagnosis 150/186 (81) 69/83 (83) 86/108 (80) 44/49 (90) 106/117 (91) 49/54 (91) Complicated skin and skin structure infections 61/72 (85) 31/34 (91) 37/43 (86) 22/23 (96) 46/49 (94) 26/27 (96) Nosocomial pneumonia 13/18 (72) 11/12 (92) 5/6 (83) 4/4 (100) 7/7 (100) 5/5 (100) Table 17. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Pediatric Patients with Infections due to Gram-positive Pathogens Pathogen Microbiologically Evaluable Linezolid n/N (%) Vancomycin n/N (%) Vancomycin-resistant Enterococcus faecium 6/8 (75) Includes data from 7 patients enrolled in the open-label extension of this study. 0/0 (-) Staphylococcus aureus 36/38 (95) 23/24 (96) Methicillin-resistant S. aureus 16/17 (94) 9/9 (100) Streptococcus pyogenes 2/2 (100) 1/2 (50)"],"pharmacodynamics":["12.2 Pharmacodynamics In a randomized, positive- and placebo-controlled crossover thorough QT study, 40 healthy subjects were administered a single linezolid 600 mg dose via a 1 hour IV infusion, a single linezolid 1,200 mg dose via a 1 hour IV infusion, placebo, and a single oral dose of positive control. At both the 600 mg and 1,200 mg linezolid doses, no significant effect on QTc interval was detected at peak plasma concentration or at any other time."],"pharmacokinetics":["12.3 Pharmacokinetics The mean pharmacokinetic parameters of linezolid in adults after single and multiple oral and intravenous doses are summarized in Table 8. Plasma concentrations of linezolid at steady-state after oral doses of 600 mg given every 12 hours are shown in Figure 1. Table 8. Mean (Standard Deviation) Pharmacokinetic Parameters of Linezolid in Adults Dose of Linezolid C max mcg/mL C min mcg/mL T max hrs AUC AUC for single dose = AUC 0-∞ ; for multiple-dose = AUC 0-τ mcg • h/mL t 1/2 hrs CL mL/min 400 mg tablet single dose Data dose-normalized from 375 mg 8.10 --- 1.52 55.10 5.20 146 (1.83) (1.01) (25.00) (1.50) (67) every 12 hours 11.00 3.08 1.12 73.40 4.69 110 (4.37) (2.25) (0.47) (33.50) (1.70) (49) 600 mg tablet single dose 12.70 --- 1.28 91.40 4.26 127 (3.96) (0.66) (39.30) (1.65) (48) every 12 hours 21.20 6.15 1.03 138.00 5.40 80 (5.78) (2.94) (0.62) (42.10) (2.06) (29) 600 mg IV injection Data dose-normalized from 625 mg, intravenous dose was given as 0.5-hour infusion. C max = Maximum plasma concentration; C min = Minimum plasma concentration; T max = Time to C max ; AUC = Area under concentration-time curve; t 1/2 = Elimination half-life; CL = Systemic clearance single dose 12.90 --- 0.50 80.20 4.40 138 (1.60) (0.10) (33.30) (2.40) (39) every 12 hours 15.10 3.68 0.51 89.70 4.80 123 (2.52) (2.36) (0.03) (31.00) (1.70) (40) 600 mg oral suspension single dose 11.00 --- 0.97 80.80 4.60 141 (2.76) (0.88) (35.10) (1.71) (45) Figure 1. Plasma Concentrations of Linezolid in Adults at Steady-State Following Oral Dosing Every 12 Hours (Mean ± Standard Deviation, n=16) Absorption : Linezolid is extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%. Therefore, linezolid may be given orally or intravenously without dose adjustment. Linezolid may be administered without regard to the timing of meals. The time to reach the maximum concentration is delayed from 1.5 hours to 2.2 hours and C max is decreased by about 17% when high fat food is given with linezolid. However, the total exposure measured as AUC 0-∞ is similar under both conditions. Distribution : Animal and human pharmacokinetic studies have demonstrated that linezolid readily distributes to well-perfused tissues. The plasma protein binding of linezolid is approximately 31% and is concentration-independent. The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers. Linezolid concentrations have been determined in various fluids from a limited number of subjects in Phase 1 volunteer studies following multiple dosing of linezolid. The ratio of linezolid in saliva relative to plasma was 1.2 to 1 and the ratio of linezolid in sweat relative to plasma was 0.55 to 1. Metabolism : Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite (B). Formation of metabolite A is presumed to be formed via an enzymatic pathway whereas metabolite B is mediated by a non-enzymatic chemical oxidation mechanism in vitro . In vitro studies have demonstrated that linezolid is minimally metabolized and may be mediated by human cytochrome P450. However, the metabolic pathway of linezolid is not fully understood. Excretion : Nonrenal clearance accounts for approximately 65% of the total clearance of linezolid. Under steady-state conditions, approximately 30% of the dose appears in the urine as linezolid, 40% as metabolite B, and 10% as metabolite A. The mean renal clearance of linezolid is 40 mL/min which suggests net tubular reabsorption. Virtually no linezolid appears in the feces, while approximately 6% of the dose appears in the feces as metabolite B, and 3% as metabolite A. A small degree of nonlinearity in clearance was observed with increasing doses of linezolid, which appears to be due to lower renal and nonrenal clearance of linezolid at higher concentrations. However, the difference in clearance was small and was not reflected in the apparent elimination half-life. Specific Populations : Geriatric Patients : The pharmacokinetics of linezolid are not significantly altered in elderly patients (65 years or older). Therefore, dose adjustment for geriatric patients is not necessary. Pediatric Patients : The pharmacokinetics of linezolid following a single intravenous dose were investigated in pediatric patients ranging in age from birth through 17 years (including premature and full-term neonates), in healthy adolescent subjects ranging in age from 12 through 17 years, and in pediatric patients ranging in age from 1 week through 12 years. The pharmacokinetic parameters of linezolid are summarized in Table 9 for the pediatric populations studied and healthy adult subjects after administration of single intravenous doses. The C max and the volume of distribution (V ss ) of linezolid are similar regardless of age in pediatric patients. However, plasma clearance of linezolid varies as a function of age. With the exclusion of pre-term neonates less than one week of age, weight-based clearance is most rapid in the youngest age groups ranging from < 1 week old to 11 years, resulting in lower single-dose systemic exposure (AUC) and a shorter half-life as compared with adults. As the age of pediatric patients increases, the weight-based clearance of linezolid gradually decreases, and by adolescence mean clearance values approach those observed for the adult population. There is increased inter-subject variability in linezolid clearance and systemic drug exposure (AUC) across all pediatric age groups as compared with adults. Similar mean daily AUC values were observed in pediatric patients from birth to 11 years of age dosed every 8 hours relative to adolescents or adults dosed every 12 hours. Therefore, the dosage for pediatric patients up to 11 years of age should be 10 mg/kg every 8 hours. Pediatric patients 12 years and older should receive 600 mg every 12 hours [see Dosage and Administration ( 2 )]. Table 9. Pharmacokinetic Parameters of Linezolid in Pediatrics and Adults Following a Single Intravenous Infusion of 10 mg/kg or 600 mg Linezolid (Mean: (%CV); [Min, Max Values]) Age Group C max mcg/mL V ss L/kg AUC AUC = Single dose AUC 0-∞ ** In this data set, “pre-term” is defined as <34 weeks gestational age (Note: Only 1 patient enrolled was pre-term with a postnatal age between 1 week and 28 days) *** In this data set, “full-term” is defined as ≥34 weeks gestational age mcg ● h/mL t 1/2 hrs CL mL/min/kg Neonatal Patients Pre-term ˂ 1 week (N=9) Dose of 10 mg/kg 12.7 (30%) [9.6, 22.2] 0.81 (24%) [0.43, 1.05] 108 (47%) [41, 191] 5.6 (46%) [2.4, 9.8] 2.0 (52%) [0.9, 4.0] Full-term *** < 1 week (N=10) 11.5 (24%) [8.0, 18.3] 0.78 (20%) [0.45, 0.96] 55 (47%) [19, 103] 3.0 (55%) [1.3, 6.1] 3.8 (55%) [1.5, 8.8] Full-term *** ≥ 1 week to ≤ 28 days (N=10) 12.9 (28%) [7.7, 21.6] 0.66 (29%) [0.35, 1.06] 34 (21%) [23, 50] 1.5 (17%) [1.2, 1.9] 5.1 (22%) [3.3, 7.2] Infant Patients > 28 days to < 3 Months (N=12) 11.0 (27%) [7.2, 18.0] 0.79 (26%) [0.42, 1.08] 33 (26%) [17, 48] 1.8 (28%) [1.2, 2.8] 5.4 (32%) [3.5, 9.9] Pediatric Patients 3 months through 11 years (N=59) 15.1 (30%) [6.8, 36.7] 0.69 (28%) [0.31, 1.50] 58 (54%) [19, 153] 2.9 (53%) [0.9, 8.0] 3.8 (53%) [1.0, 8.5] Adolescent Subjects and Patients 12 through 17 years Dose of 600 mg or 10 mg/kg up to a maximum of 600 mg (N=36) 16.7 (24%) [9.9, 28.9] 0.61 (15%) [0.44, 0.79] 95 (44%) [32, 178] 4.1 (46%) [1.3, 8.1] 2.1 (53%) [0.9, 5.2] Adult Subjects Dose normalized to 600 mg C max = Maximum plasma concentration; Vss= Volume of distribution; AUC = Area under concentration-time curve; t 1/2 = Apparent elimination half-life; CL = Systemic clearance normalized for body weight (N= 29) 12.5 (21%) [8.2, 19.3] 0.65 (16%) [0.45, 0.84] 91 (33%) [53, 155] 4.9 (35%) [1.8, 8.3] 1.7 (34%) [0.9, 3.3] Gender : Females have a slightly lower volume of distribution of linezolid than males. Plasma concentrations are higher in females than in males, which is partly due to body weight differences. After a 600-mg dose, mean oral clearance is approximately 38% lower in females than in males. However, there are no significant gender differences in mean apparent elimination-rate constant or half-life. Thus, drug exposure in females is not expected to substantially increase beyond levels known to be well tolerated. Therefore, dose adjustment by gender does not appear to be necessary. Renal Impairment : The pharmacokinetics of the parent drug, linezolid, are not altered in patients with any degree of renal impairment; however, the two primary metabolites of linezolid accumulate in patients with renal impairment, with the amount of accumulation increasing with the severity of renal dysfunction (see Table 10). The pharmacokinetics of linezolid and its two metabolites have also been studied in patients with end-stage renal disease (ESRD) receiving hemodialysis. In the ESRD study, 14 patients were dosed with linezolid 600 mg every 12 hours for 14.5 days (see Table 11). Because similar plasma concentrations of linezolid are achieved regardless of renal function, no dose adjustment is recommended for patients with renal impairment. However, given the absence of information on the clinical significance of accumulation of the primary metabolites, use of linezolid in patients with renal impairment should be weighed against the potential risks of accumulation of these metabolites. Both linezolid and the two metabolites are eliminated by hemodialysis. No information is available on the effect of peritoneal dialysis on the pharmacokinetics of linezolid. Approximately 30% of a dose was eliminated in a 3-hour hemodialysis session beginning 3 hours after the dose of linezolid was administered; therefore, linezolid should be given after hemodialysis. Table 10. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Patients with Varying Degrees of Renal Impairment After a Single 600 mg Oral Dose of Linezolid Parameter Healthy Subjects CL CR > 80 mL/min Moderate Renal Impairment 30 < CL CR < 80 mL/min Severe Renal Impairment 10 < CL CR < 30 mL/min LINEZOLID AUC 0-∞ , mcg h/mL 110 (22) 128 (53) 127 (66) t 1/2 , hours 6.4 (2.2) 6.1 (1.7) 7.1 (3.7) METABOLITE A AUC 0-48 , mcg h/mL 7.6 (1.9) 11.7 (4.3) 56.5 (30.6) t 1/2 , hours 6.3 (2.1) 6.6 (2.3) 9.0 (4.6) METABOLITE B Metabolite B is the major metabolite of linezolid. AUC 0-48 , mcg h/mL 30.5 (6.2) 51.1 (38.5) 203 (92) t 1/2 , hours 6.6 (2.7) 9.9 (7.4) 11.0 (3.9) Table 11. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Subjects with End-Stage Renal Disease (ESRD) After the Administration of 600 mg Linezolid Every 12 Hours for 14.5 Days Parameter ESRD Subjects Between hemodialysis sessions. LINEZOLID AUC 0-12 , mcg h/mL (after last dose) 181 (52.3) t 1/2 , h (after last dose) 8.3 (2.4) METABOLITE A AUC 0-12 , mcg h/mL (after last dose) 153 (40.6) t 1/2 , h (after last dose) 15.9 (8.5) METABOLITE B Metabolite B is the major metabolite of linezolid. AUC 0-12 , mcg h/mL (after last dose) 356 (99.7) t 1/2 , h (after last dose) 34.8 (23.1) Hepatic Impairment : The pharmacokinetics of linezolid are not altered in patients (n=7) with mild-to-moderate hepatic impairment (Child-Pugh class A or B). On the basis of the available information, no dose adjustment is recommended for patients with mild-to-moderate hepatic impairment. The pharmacokinetics of linezolid in patients with severe hepatic impairment have not been evaluated. Drug Interactions : Drugs Metabolized by Cytochrome P450 : Linezolid is not an inducer of cytochrome P450 (CYP450) in rats. In addition, linezolid does not inhibit the activities of clinically significant human CYP isoforms (e.g., 1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Therefore, linezolid is not expected to affect the pharmacokinetics of other drugs metabolized by these major enzymes. Concurrent administration of linezolid does not substantially alter the pharmacokinetic characteristics of (S)-warfarin, which is extensively metabolized by CYP2C9. Drugs such as warfarin and phenytoin, which are CYP2C9 substrates, may be given with linezolid without changes in dosage regimen. Antibacterial Drugs : Aztreonam : The pharmacokinetics of linezolid or aztreonam are not altered when administered together. Gentamicin : The pharmacokinetics of linezolid or gentamicin are not altered when administered together. Antioxidants : The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. Subjects were administered a 600 mg oral dose of linezolid on Day 1, and another 600 mg dose of linezolid on Day 8. On Days 2-9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC 0-∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co‑administered with Vitamin E. No linezolid dose adjustment is recommended during co-administration with Vitamin C or Vitamin E. Strong CYP 3A4 Inducers : Rifampin : The effect of rifampin on the pharmacokinetics of linezolid was evaluated in a study of 16 healthy adult males. Volunteers were administered oral linezolid 600 mg twice daily for 5 doses with and without rifampin 600 mg once daily for 8 days. Co-administration of rifampin with linezolid resulted in a 21% decrease in linezolid C max [90% CI, 15% to 27%] and a 32% decrease in linezolid AUC 0-12 [90% CI, 27% to 37%]. The clinical significance of this interaction is unknown. The mechanism of this interaction is not fully understood and may be related to the induction of hepatic enzymes. Other strong inducers of hepatic enzymes (e.g. carbamazepine, phenytoin, phenobarbital) could cause a similar or smaller decrease in linezolid exposure. Monoamine Oxidase Inhibition : Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents : Some individuals receiving linezolid may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Tyramine : A significant pressor response has been observed in normal adult subjects receiving linezolid and tyramine doses of more than 100 mg. Therefore, patients receiving linezolid need to avoid consuming large amounts of foods or beverages with high tyramine content [see Patient Counseling Information ( 17 )]. Pseudoephedrine HCl or Phenylpropanolamine HCl : A reversible enhancement of the pressor response of either pseudoephedrine HCl (PSE) or phenylpropanolamine HCl (PPA) is observed when linezolid is administered to healthy normotensive subjects [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7 )]. A similar study has not been conducted in hypertensive patients. The interaction studies conducted in normotensive subjects evaluated the blood pressure and heart rate effects of placebo, PPA or PSE alone, linezolid alone, and the combination of steady-state linezolid (600 mg every 12 hours for 3 days) with two doses of PPA (25 mg) or PSE (60 mg) given 4 hours apart. Heart rate was not affected by any of the treatments. Blood pressure was increased with both combination treatments. Maximum blood pressure levels were seen 2 to 3 hours after the second dose of PPA or PSE, and returned to baseline 2 to 3 hours after peak. The results of the PPA study follow, showing the mean (and range) maximum systolic blood pressure in mm Hg: placebo = 121 (103 to 158); linezolid alone = 120 (107 to 135); PPA alone = 125 (106 to 139); PPA with linezolid = 147 (129 to 176). The results from the PSE study were similar to those in the PPA study. The mean maximum increase in systolic blood pressure over baseline was 32 mm Hg (range: 20-52 mm Hg) and 38 mm Hg (range: 18 to 79 mm Hg) during co-administration of linezolid with pseudoephedrine or phenylpropanolamine, respectively. Serotonergic Agents : Dextromethorphan : The potential drug-drug interaction with dextromethorphan was studied in healthy volunteers. Subjects were administered dextromethorphan (two 20-mg doses given 4 hours apart) with or without linezolid. No serotonin syndrome effects (confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia) have been observed in normal subjects receiving linezolid and dextromethorphan. figure-1"],"adverse_reactions":["6 ADVERSE REACTIONS Most common adverse reactions (>5% of adult and/or pediatric patients treated with linezolid) include: diarrhea, vomiting, headache, nausea, and anemia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions ()] Peripheral and Optic Neuropathy [see Warnings and Precautions ()] Serotonin Syndrome [see Warnings and Precautions ()] Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions ()] Lactic Acidosis [see Warnings and Precautions ()] Convulsions [see Warnings and Precautions ()] Rhabdomyolysis [see Warnings and Precautions ()] Hypoglycemia [see Warnings and Precautions ()] Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) [see Warnings and Precautions ()] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adults : The safety of linezolid formulations was evaluated in 2,046 adult patients enrolled in seven Phase 3 comparator-controlled clinical trials, who were treated for up to 28 days. Of the patients treated for uncomplicated skin and skin structure infections (uSSSIs), 25.4% of linezolid-treated and 19.6% of comparator-treated patients experienced at least one drug-related adverse event. For all other indications, 20.4% of linezolid-treated and 14.3% of comparator-treated patients experienced at least one drug-related adverse event. Table 2 shows the incidence of all-causality, treatment-emergent adverse reactions reported in at least 1% of adult patients in these trials by dose of linezolid. Table 2. Incidence (%) of Treatment-Emergent Adverse Reactions Occurring in >1% of Adult Patients Treated with Linezolid in Comparator-Controlled Clinical Trials Uncomplicated Skin and Skin Structure Infections All Other Indications ADVERSE REACTIONS Linezolid 400 mg by mouth every 12 hours (n=548) Clarithromycin 250 mg by mouth every 12 hours (n=537) Linezolid 600 mg every 12 hours (n=1498) All Other Comparators Comparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12 hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours. (n=1464) Headache 8.8 8.4 5.7 4.4 Diarrhea 8.2 6.1 8.3 6.4 Nausea 5.1 4.5 6.6 4.6 Vomiting 2.0 1.5 4.3 2.3 Dizziness 2.6 3.0 1.8 1.5 Rash 1.1 1.1 2.3 2.6 Anemia 0.4 0 2.1 1.4 Taste alteration 1.8 2.0 1.0 0.3 Vaginal moniliasis 1.8 1.3 1.1 0.5 Oral moniliasis 0.5 0 1.7 1.0 Abnormal liver function tests 0.4 0.2 1.6 0.8 Fungal infection 1.5 0.2 0.3 0.2 Tongue discoloration 1.3 0 0.3 0 Localized abdominal pain 1.3 0.6 1.2 0.8 Generalized abdominal pain 0.9 0.4 1.2 1.0 Of the patients treated for uSSSIs, 3.5% of linezolid-treated and 2.4% of comparator-treated patients discontinued treatment due to drug-related adverse events. For all other indications, discontinuations due to drug-related adverse events occurred in 2.1% of linezolid-treated and 1.7% of comparator-treated patients. The most common reported drug-related adverse events leading to discontinuation of treatment were nausea, headache, diarrhea, and vomiting. Pediatric Patients : The safety of linezolid formulations was evaluated in 215 pediatric patients ranging in age from birth through 11 years, and in 248 pediatric patients aged 5 through 17 years (146 of these 248 were age 5 through 11 and 102 were age 12 to 17). These patients were enrolled in two Phase 3 comparator-controlled clinical trials and were treated for up to 28 days. In the study of hospitalized pediatric patients (birth through 11 years) with Gram-positive infections, who were randomized 2 to 1 (linezolid: vancomycin), mortality was 6% (13/215) in the linezolid arm and 3% (3/101) in the vancomycin arm. However, given the severe underlying illness in the patient population, no causality could be established. Of the pediatric patients treated for uSSSIs, 19.2% of linezolid-treated and 14.1% of comparator-treated patients experienced at least one drug-related adverse event. For all other indications, 18.8% of linezolid-treated and 34.3% of comparator-treated patients experienced at least one drug-related adverse event. Table 3 shows the incidence of all-causality, treatment-emergent adverse reactions reported in more than 1% of pediatric patients (and more than 1 patient) in either treatment group in the comparator-controlled Phase 3 trials. Table 3. Incidence (%) of Treatment-Emergent Adverse Reactions Occurring in >1% of Pediatric Patients (and >1 Patient) in Either Treatment Group in Comparator-Controlled Clinical Trials ADVERSE REACTIONS Uncomplicated Skin and Skin Structure Infections Patients 5 through 11 years of age received linezolid 10 mg/kg by mouth every 12 hours or cefadroxil 15 mg/kg by mouth every 12 hours. Patients 12 years or older received linezolid 600 mg by mouth every 12 hours or cefadroxil 500 mg by mouth every 12 hours. All Other Indications Patients from birth through 11 years of age received linezolid 10 mg/kg intravenously or by mouth every 8 hours or vancomycin 10 to 15 mg/kg intravenously every 6 to 24 hours, depending on age and renal clearance. Linezolid (n=248) Cefadroxil (n=251) Linezolid (n=215) Vancomycin (n=101) Diarrhea 7.8 8.0 10.8 12.1 Vomiting 2.9 6.4 9.4 9.1 Headache 6.5 4.0 0.9 0 Anemia 0 0 5.6 7.1 Thrombocytopenia 0 0 4.7 2.0 Nausea 3.7 3.2 1.9 0 Generalized abdominal pain 2.4 2.8 0.9 2.0 Localized abdominal pain 2.4 2.8 0.5 1.0 Loose stools 1.6 0.8 2.3 3.0 Eosinophilia 0.4 0.8 1.9 1.0 Pruritus at non-application site 0.8 0.4 1.4 2.0 Vertigo 1.2 0.4 0 0 Of the pediatric patients treated for uSSSIs, 1.6% of linezolid-treated and 2.4% of comparator-treated patients discontinued treatment due to drug-related adverse events. For all other indications, discontinuations due to drug-related adverse events occurred in 0.9% of linezolid-treated and 6.1% of comparator-treated patients. Laboratory Abnormalities : Linezolid has been associated with thrombocytopenia when used in doses up to and including 600 mg every 12 hours for up to 28 days. In Phase 3 comparator-controlled trials, the percentage of adult patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 2.4% (range among studies: 0.3 to 10%) with linezolid and 1.5% (range among studies: 0.4 to 7%) with a comparator. In a study of hospitalized pediatric patients ranging in age from birth through 11 years, the percentage of patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 12.9% with linezolid and 13.4% with vancomycin. In an outpatient study of pediatric patients aged from 5 through 17 years, the percentage of patients who developed a substantially low platelet count was 0% with linezolid and 0.4% with cefadroxil. Thrombocytopenia associated with the use of linezolid appears to be dependent on duration of therapy (generally greater than 2 weeks of treatment). The platelet counts for most patients returned to the normal range/baseline during the follow-up period. No related clinical adverse events were identified in Phase 3 clinical trials in patients developing thrombocytopenia. Bleeding events were identified in thrombocytopenic patients in a compassionate use program for linezolid; the role of linezolid in these events cannot be determined [see Warnings and Precautions ( 5.1 )]. Changes seen in other laboratory parameters, without regard to drug relationship, revealed no substantial differences between linezolid and the comparators. These changes were generally not clinically significant, did not lead to discontinuation of therapy, and were reversible. The incidence of adult and pediatric patients with at least one substantially abnormal hematologic or serum chemistry value is presented in Tables 4, 5, 6, and 7. Table 4. Percent of Adult Patients who Experienced at Least One Substantially Abnormal <75% (<50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; <75% (<50% for neutrophils) of LLN and of baseline for values abnormal at baseline. Hematology Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid Laboratory Assay Uncomplicated Skin and Skin Structure Infections All Other Indications Linezolid 400 mg every 12 hours Clarithromycin 250 mg every 12 hours Linezolid 600 mg every 12 hours All Other Comparators Comparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12 hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours. Hemoglobin (g/dL) 0.9 0.0 7.1 6.6 Platelet count (x 10 3 /mm 3 ) 0.7 0.8 3.0 1.8 WBC (x 10 3 /mm 3 ) 0.2 0.6 2.2 1.3 Neutrophils (x 10 3 /mm 3 ) 0.0 0.2 1.1 1.2 Table 5. Percent of Adult Patients who Experienced at Least One Substantially Abnormal >2 x Upper Limit of Normal (ULN) for values normal at baseline; >2 x ULN and >2 x baseline for values abnormal at baseline. Serum Chemistry Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid Laboratory Assay Uncomplicated Skin and Skin Structure Infections All Other Indications Linezolid 400 mg every 12 hours Clarithromycin 250 mg every 12 hours Linezolid 600 mg every 12 hours All Other Comparators Comparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12 hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours. AST (U/L) 1.7 1.3 5.0 6.8 ALT (U/L) 1.7 1.7 9.6 9.3 LDH (U/L) 0.2 0.2 1.8 1.5 Alkaline phosphatase (U/L) 0.2 0.2 3.5 3.1 Lipase (U/L) 2.8 2.6 4.3 4.2 Amylase (U/L) 0.2 0.2 2.4 2.0 Total bilirubin (mg/dL) 0.2 0.0 0.9 1.1 BUN (mg/dL) 0.2 0.0 2.1 1.5 Creatinine (mg/dL) 0.2 0.0 0.2 0.6 Table 6. Percent of Pediatric Patients who Experienced at Least One Substantially Abnormal <75% (<50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; <75% (<50% for neutrophils) of LLN and <75% (<50% for neutrophils, <90% for hemoglobin if baseline 2 x Upper Limit of Normal (ULN) for values normal at baseline; >2 x ULN and >2 (>1.5 for total bilirubin) x baseline for values abnormal at baseline. Serum Chemistry Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid Laboratory Assay Uncomplicated Skin and Skin Structure Infections Patients 5 through 11 years of age received linezolid 10 mg/kg by mouth every 12 hours or cefadroxil 15 mg/kg by mouth every 12 hours. Patients 12 years or older received linezolid 600 mg by mouth every 12 hours or cefadroxil 500 mg by mouth every 12 hours. All Other Indications Patients from birth through 11 years of age received linezolid 10 mg/kg intravenously or by mouth every 8 hours or vancomycin 10 to 15 mg/kg intravenously every 6-24 hours, depending on age and renal clearance. Linezolid Cefadroxil Linezolid Vancomycin ALT (U/L) 0.0 0.0 10.1 12.5 Lipase (U/L) 0.4 1.2 --- --- Amylase (U/L) --- --- 0.6 1.3 Total bilirubin (mg/dL) --- --- 6.3 5.2 Creatinine (mg/dL) 0.4 0.0 2.4 1.0 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of linezolid. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: • Anaphylaxis, angioedema, bullous skin disorders including severe cutaneous adverse reactions (SCAR) such as toxic epidermal necrolysis and Stevens-Johnson syndrome, and hypersensitivity vasculitis. • Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia). Thrombocytopenia has been reported more often in patients with severe renal impairment and in patients with moderate to severe hepatic impairment [see Warnings and Precautions ( 5.1 )]; sideroblastic anemia. • Peripheral neuropathy, and optic neuropathy sometimes progressing to loss of vision [see Warnings and Precautions ( 5.2 )]. • Serotonin syndrome has been reported in patients receiving concomitant serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and opioids, and linezolid [see Warnings and Precautions ( 5.3 )]. • Lactic acidosis [see Warnings and Precautions ( 5.7 )]. Although these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days, these events have also been reported in patients receiving shorter courses of therapy. • Convulsions [see Warnings and Precautions ( 5.8 )]. • Rhabdomyolysis [see Warnings and Precautions ( 5.9 )]. • Hypoglycemia, including symptomatic episodes [see Warnings and Precautions ( 5.10 )]. • Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) [see Warnings and Precautions ( 5.11 )]. • Superficial tooth discoloration and tongue discoloration have been reported with the use of linezolid. The tooth discoloration was removable with professional dental cleaning (manual descaling) in cases with known outcome."],"contraindications":["4 CONTRAINDICATIONS • Known hypersensitivity to linezolid or any of the other product components. ( 4.1 ) • Patients taking any monoamine oxidase inhibitors (MAOI) or within two weeks of taking an MAOI. ( 4.2 ) 4.1 Hypersensitivity Linezolid formulations are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components . 4.2 Monoamine Oxidase Inhibitors Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product."],"drug_interactions":["7 DRUG INTERACTIONS Monoamine oxidase inhibitors and potential for interaction with adrenergic and serotonergic agents. ( 4.2 , 5.3 , 5.6 , 7 , 12.3 ) 7.1 Monoamine Oxidase Inhibitors Linezolid is a reversible, nonselective inhibitor of monoamine oxidase [see Contraindications ( 4.2 ) and Clinical Pharmacology ( 12.3 )]. 7.2 Adrenergic and Serotonergic Agents Linezolid has the potential for interaction with adrenergic and serotonergic agents [see Warnings and Precautions ( 5.3 , 5.6 ) and Clinical Pharmacology ( 12.3 )] ."],"mechanism_of_action":["12.1 Mechanism of Action Linezolid is an antibacterial drug [see Microbiology ( 12.4 )] ."],"recent_major_changes":["Warnings and Precautions, Myelosuppression ( 5.1 ) Warnings and Precautions, Rhabdomyolysis ( 5.9 ) 7/2023 6/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Linezolid is an antibacterial drug [see Microbiology ( 12.4 )] . 12.2 Pharmacodynamics In a randomized, positive- and placebo-controlled crossover thorough QT study, 40 healthy subjects were administered a single linezolid 600 mg dose via a 1 hour IV infusion, a single linezolid 1,200 mg dose via a 1 hour IV infusion, placebo, and a single oral dose of positive control. At both the 600 mg and 1,200 mg linezolid doses, no significant effect on QTc interval was detected at peak plasma concentration or at any other time. 12.3 Pharmacokinetics The mean pharmacokinetic parameters of linezolid in adults after single and multiple oral and intravenous doses are summarized in Table 8. Plasma concentrations of linezolid at steady-state after oral doses of 600 mg given every 12 hours are shown in Figure 1. Table 8. Mean (Standard Deviation) Pharmacokinetic Parameters of Linezolid in Adults Dose of Linezolid C max mcg/mL C min mcg/mL T max hrs AUC AUC for single dose = AUC 0-∞ ; for multiple-dose = AUC 0-τ mcg • h/mL t 1/2 hrs CL mL/min 400 mg tablet single dose Data dose-normalized from 375 mg 8.10 --- 1.52 55.10 5.20 146 (1.83) (1.01) (25.00) (1.50) (67) every 12 hours 11.00 3.08 1.12 73.40 4.69 110 (4.37) (2.25) (0.47) (33.50) (1.70) (49) 600 mg tablet single dose 12.70 --- 1.28 91.40 4.26 127 (3.96) (0.66) (39.30) (1.65) (48) every 12 hours 21.20 6.15 1.03 138.00 5.40 80 (5.78) (2.94) (0.62) (42.10) (2.06) (29) 600 mg IV injection Data dose-normalized from 625 mg, intravenous dose was given as 0.5-hour infusion. C max = Maximum plasma concentration; C min = Minimum plasma concentration; T max = Time to C max ; AUC = Area under concentration-time curve; t 1/2 = Elimination half-life; CL = Systemic clearance single dose 12.90 --- 0.50 80.20 4.40 138 (1.60) (0.10) (33.30) (2.40) (39) every 12 hours 15.10 3.68 0.51 89.70 4.80 123 (2.52) (2.36) (0.03) (31.00) (1.70) (40) 600 mg oral suspension single dose 11.00 --- 0.97 80.80 4.60 141 (2.76) (0.88) (35.10) (1.71) (45) Figure 1. Plasma Concentrations of Linezolid in Adults at Steady-State Following Oral Dosing Every 12 Hours (Mean ± Standard Deviation, n=16) Absorption : Linezolid is extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2 hours after dosing, and the absolute bioavailability is approximately 100%. Therefore, linezolid may be given orally or intravenously without dose adjustment. Linezolid may be administered without regard to the timing of meals. The time to reach the maximum concentration is delayed from 1.5 hours to 2.2 hours and C max is decreased by about 17% when high fat food is given with linezolid. However, the total exposure measured as AUC 0-∞ is similar under both conditions. Distribution : Animal and human pharmacokinetic studies have demonstrated that linezolid readily distributes to well-perfused tissues. The plasma protein binding of linezolid is approximately 31% and is concentration-independent. The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers. Linezolid concentrations have been determined in various fluids from a limited number of subjects in Phase 1 volunteer studies following multiple dosing of linezolid. The ratio of linezolid in saliva relative to plasma was 1.2 to 1 and the ratio of linezolid in sweat relative to plasma was 0.55 to 1. Metabolism : Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite (B). Formation of metabolite A is presumed to be formed via an enzymatic pathway whereas metabolite B is mediated by a non-enzymatic chemical oxidation mechanism in vitro . In vitro studies have demonstrated that linezolid is minimally metabolized and may be mediated by human cytochrome P450. However, the metabolic pathway of linezolid is not fully understood. Excretion : Nonrenal clearance accounts for approximately 65% of the total clearance of linezolid. Under steady-state conditions, approximately 30% of the dose appears in the urine as linezolid, 40% as metabolite B, and 10% as metabolite A. The mean renal clearance of linezolid is 40 mL/min which suggests net tubular reabsorption. Virtually no linezolid appears in the feces, while approximately 6% of the dose appears in the feces as metabolite B, and 3% as metabolite A. A small degree of nonlinearity in clearance was observed with increasing doses of linezolid, which appears to be due to lower renal and nonrenal clearance of linezolid at higher concentrations. However, the difference in clearance was small and was not reflected in the apparent elimination half-life. Specific Populations : Geriatric Patients : The pharmacokinetics of linezolid are not significantly altered in elderly patients (65 years or older). Therefore, dose adjustment for geriatric patients is not necessary. Pediatric Patients : The pharmacokinetics of linezolid following a single intravenous dose were investigated in pediatric patients ranging in age from birth through 17 years (including premature and full-term neonates), in healthy adolescent subjects ranging in age from 12 through 17 years, and in pediatric patients ranging in age from 1 week through 12 years. The pharmacokinetic parameters of linezolid are summarized in Table 9 for the pediatric populations studied and healthy adult subjects after administration of single intravenous doses. The C max and the volume of distribution (V ss ) of linezolid are similar regardless of age in pediatric patients. However, plasma clearance of linezolid varies as a function of age. With the exclusion of pre-term neonates less than one week of age, weight-based clearance is most rapid in the youngest age groups ranging from < 1 week old to 11 years, resulting in lower single-dose systemic exposure (AUC) and a shorter half-life as compared with adults. As the age of pediatric patients increases, the weight-based clearance of linezolid gradually decreases, and by adolescence mean clearance values approach those observed for the adult population. There is increased inter-subject variability in linezolid clearance and systemic drug exposure (AUC) across all pediatric age groups as compared with adults. Similar mean daily AUC values were observed in pediatric patients from birth to 11 years of age dosed every 8 hours relative to adolescents or adults dosed every 12 hours. Therefore, the dosage for pediatric patients up to 11 years of age should be 10 mg/kg every 8 hours. Pediatric patients 12 years and older should receive 600 mg every 12 hours [see Dosage and Administration ( 2 )]. Table 9. Pharmacokinetic Parameters of Linezolid in Pediatrics and Adults Following a Single Intravenous Infusion of 10 mg/kg or 600 mg Linezolid (Mean: (%CV); [Min, Max Values]) Age Group C max mcg/mL V ss L/kg AUC AUC = Single dose AUC 0-∞ ** In this data set, “pre-term” is defined as <34 weeks gestational age (Note: Only 1 patient enrolled was pre-term with a postnatal age between 1 week and 28 days) *** In this data set, “full-term” is defined as ≥34 weeks gestational age mcg ● h/mL t 1/2 hrs CL mL/min/kg Neonatal Patients Pre-term ˂ 1 week (N=9) Dose of 10 mg/kg 12.7 (30%) [9.6, 22.2] 0.81 (24%) [0.43, 1.05] 108 (47%) [41, 191] 5.6 (46%) [2.4, 9.8] 2.0 (52%) [0.9, 4.0] Full-term *** < 1 week (N=10) 11.5 (24%) [8.0, 18.3] 0.78 (20%) [0.45, 0.96] 55 (47%) [19, 103] 3.0 (55%) [1.3, 6.1] 3.8 (55%) [1.5, 8.8] Full-term *** ≥ 1 week to ≤ 28 days (N=10) 12.9 (28%) [7.7, 21.6] 0.66 (29%) [0.35, 1.06] 34 (21%) [23, 50] 1.5 (17%) [1.2, 1.9] 5.1 (22%) [3.3, 7.2] Infant Patients > 28 days to < 3 Months (N=12) 11.0 (27%) [7.2, 18.0] 0.79 (26%) [0.42, 1.08] 33 (26%) [17, 48] 1.8 (28%) [1.2, 2.8] 5.4 (32%) [3.5, 9.9] Pediatric Patients 3 months through 11 years (N=59) 15.1 (30%) [6.8, 36.7] 0.69 (28%) [0.31, 1.50] 58 (54%) [19, 153] 2.9 (53%) [0.9, 8.0] 3.8 (53%) [1.0, 8.5] Adolescent Subjects and Patients 12 through 17 years Dose of 600 mg or 10 mg/kg up to a maximum of 600 mg (N=36) 16.7 (24%) [9.9, 28.9] 0.61 (15%) [0.44, 0.79] 95 (44%) [32, 178] 4.1 (46%) [1.3, 8.1] 2.1 (53%) [0.9, 5.2] Adult Subjects Dose normalized to 600 mg C max = Maximum plasma concentration; Vss= Volume of distribution; AUC = Area under concentration-time curve; t 1/2 = Apparent elimination half-life; CL = Systemic clearance normalized for body weight (N= 29) 12.5 (21%) [8.2, 19.3] 0.65 (16%) [0.45, 0.84] 91 (33%) [53, 155] 4.9 (35%) [1.8, 8.3] 1.7 (34%) [0.9, 3.3] Gender : Females have a slightly lower volume of distribution of linezolid than males. Plasma concentrations are higher in females than in males, which is partly due to body weight differences. After a 600-mg dose, mean oral clearance is approximately 38% lower in females than in males. However, there are no significant gender differences in mean apparent elimination-rate constant or half-life. Thus, drug exposure in females is not expected to substantially increase beyond levels known to be well tolerated. Therefore, dose adjustment by gender does not appear to be necessary. Renal Impairment : The pharmacokinetics of the parent drug, linezolid, are not altered in patients with any degree of renal impairment; however, the two primary metabolites of linezolid accumulate in patients with renal impairment, with the amount of accumulation increasing with the severity of renal dysfunction (see Table 10). The pharmacokinetics of linezolid and its two metabolites have also been studied in patients with end-stage renal disease (ESRD) receiving hemodialysis. In the ESRD study, 14 patients were dosed with linezolid 600 mg every 12 hours for 14.5 days (see Table 11). Because similar plasma concentrations of linezolid are achieved regardless of renal function, no dose adjustment is recommended for patients with renal impairment. However, given the absence of information on the clinical significance of accumulation of the primary metabolites, use of linezolid in patients with renal impairment should be weighed against the potential risks of accumulation of these metabolites. Both linezolid and the two metabolites are eliminated by hemodialysis. No information is available on the effect of peritoneal dialysis on the pharmacokinetics of linezolid. Approximately 30% of a dose was eliminated in a 3-hour hemodialysis session beginning 3 hours after the dose of linezolid was administered; therefore, linezolid should be given after hemodialysis. Table 10. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Patients with Varying Degrees of Renal Impairment After a Single 600 mg Oral Dose of Linezolid Parameter Healthy Subjects CL CR > 80 mL/min Moderate Renal Impairment 30 < CL CR < 80 mL/min Severe Renal Impairment 10 < CL CR < 30 mL/min LINEZOLID AUC 0-∞ , mcg h/mL 110 (22) 128 (53) 127 (66) t 1/2 , hours 6.4 (2.2) 6.1 (1.7) 7.1 (3.7) METABOLITE A AUC 0-48 , mcg h/mL 7.6 (1.9) 11.7 (4.3) 56.5 (30.6) t 1/2 , hours 6.3 (2.1) 6.6 (2.3) 9.0 (4.6) METABOLITE B Metabolite B is the major metabolite of linezolid. AUC 0-48 , mcg h/mL 30.5 (6.2) 51.1 (38.5) 203 (92) t 1/2 , hours 6.6 (2.7) 9.9 (7.4) 11.0 (3.9) Table 11. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Subjects with End-Stage Renal Disease (ESRD) After the Administration of 600 mg Linezolid Every 12 Hours for 14.5 Days Parameter ESRD Subjects Between hemodialysis sessions. LINEZOLID AUC 0-12 , mcg h/mL (after last dose) 181 (52.3) t 1/2 , h (after last dose) 8.3 (2.4) METABOLITE A AUC 0-12 , mcg h/mL (after last dose) 153 (40.6) t 1/2 , h (after last dose) 15.9 (8.5) METABOLITE B Metabolite B is the major metabolite of linezolid. AUC 0-12 , mcg h/mL (after last dose) 356 (99.7) t 1/2 , h (after last dose) 34.8 (23.1) Hepatic Impairment : The pharmacokinetics of linezolid are not altered in patients (n=7) with mild-to-moderate hepatic impairment (Child-Pugh class A or B). On the basis of the available information, no dose adjustment is recommended for patients with mild-to-moderate hepatic impairment. The pharmacokinetics of linezolid in patients with severe hepatic impairment have not been evaluated. Drug Interactions : Drugs Metabolized by Cytochrome P450 : Linezolid is not an inducer of cytochrome P450 (CYP450) in rats. In addition, linezolid does not inhibit the activities of clinically significant human CYP isoforms (e.g., 1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Therefore, linezolid is not expected to affect the pharmacokinetics of other drugs metabolized by these major enzymes. Concurrent administration of linezolid does not substantially alter the pharmacokinetic characteristics of (S)-warfarin, which is extensively metabolized by CYP2C9. Drugs such as warfarin and phenytoin, which are CYP2C9 substrates, may be given with linezolid without changes in dosage regimen. Antibacterial Drugs : Aztreonam : The pharmacokinetics of linezolid or aztreonam are not altered when administered together. Gentamicin : The pharmacokinetics of linezolid or gentamicin are not altered when administered together. Antioxidants : The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. Subjects were administered a 600 mg oral dose of linezolid on Day 1, and another 600 mg dose of linezolid on Day 8. On Days 2-9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC 0-∞ of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co‑administered with Vitamin E. No linezolid dose adjustment is recommended during co-administration with Vitamin C or Vitamin E. Strong CYP 3A4 Inducers : Rifampin : The effect of rifampin on the pharmacokinetics of linezolid was evaluated in a study of 16 healthy adult males. Volunteers were administered oral linezolid 600 mg twice daily for 5 doses with and without rifampin 600 mg once daily for 8 days. Co-administration of rifampin with linezolid resulted in a 21% decrease in linezolid C max [90% CI, 15% to 27%] and a 32% decrease in linezolid AUC 0-12 [90% CI, 27% to 37%]. The clinical significance of this interaction is unknown. The mechanism of this interaction is not fully understood and may be related to the induction of hepatic enzymes. Other strong inducers of hepatic enzymes (e.g. carbamazepine, phenytoin, phenobarbital) could cause a similar or smaller decrease in linezolid exposure. Monoamine Oxidase Inhibition : Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents. Adrenergic Agents : Some individuals receiving linezolid may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response. Tyramine : A significant pressor response has been observed in normal adult subjects receiving linezolid and tyramine doses of more than 100 mg. Therefore, patients receiving linezolid need to avoid consuming large amounts of foods or beverages with high tyramine content [see Patient Counseling Information ( 17 )]. Pseudoephedrine HCl or Phenylpropanolamine HCl : A reversible enhancement of the pressor response of either pseudoephedrine HCl (PSE) or phenylpropanolamine HCl (PPA) is observed when linezolid is administered to healthy normotensive subjects [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7 )]. A similar study has not been conducted in hypertensive patients. The interaction studies conducted in normotensive subjects evaluated the blood pressure and heart rate effects of placebo, PPA or PSE alone, linezolid alone, and the combination of steady-state linezolid (600 mg every 12 hours for 3 days) with two doses of PPA (25 mg) or PSE (60 mg) given 4 hours apart. Heart rate was not affected by any of the treatments. Blood pressure was increased with both combination treatments. Maximum blood pressure levels were seen 2 to 3 hours after the second dose of PPA or PSE, and returned to baseline 2 to 3 hours after peak. The results of the PPA study follow, showing the mean (and range) maximum systolic blood pressure in mm Hg: placebo = 121 (103 to 158); linezolid alone = 120 (107 to 135); PPA alone = 125 (106 to 139); PPA with linezolid = 147 (129 to 176). The results from the PSE study were similar to those in the PPA study. The mean maximum increase in systolic blood pressure over baseline was 32 mm Hg (range: 20-52 mm Hg) and 38 mm Hg (range: 18 to 79 mm Hg) during co-administration of linezolid with pseudoephedrine or phenylpropanolamine, respectively. Serotonergic Agents : Dextromethorphan : The potential drug-drug interaction with dextromethorphan was studied in healthy volunteers. Subjects were administered dextromethorphan (two 20-mg doses given 4 hours apart) with or without linezolid. No serotonin syndrome effects (confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia) have been observed in normal subjects receiving linezolid and dextromethorphan. figure-1 12.4 Microbiology Mechanism of Action Linezolid is a synthetic antibacterial agent of the oxazolidinone class, which has clinical utility in the treatment of infections caused by aerobic Gram-positive bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is essential for bacterial reproduction. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci . For streptococci , linezolid was found to be bactericidal for the majority of isolates. Resistance In vitro studies have shown that point mutations in the 23S rRNA are associated with linezolid resistance. Reports of vancomycin-resistant Enterococcus faecium becoming resistant to linezolid during its clinical use have been published. There are reports of Staphylococcus aureus (methicillin-resistant) developing resistance to linezolid during clinical use. The linezolid resistance in these organisms is associated with a point mutation in the 23S rRNA (substitution of thymine for guanine at position 2576) of the organism. Organisms resistant to oxazolidinones via mutations in chromosomal genes encoding 23S rRNA or ribosomal proteins (L3 and L4) are generally cross-resistant to linezolid. Also linezolid resistance in staphylococci mediated by the enzyme methyltransferase has been reported. This resistance is mediated by the cfr (chloramphenicol-florfenicol) gene located on a plasmid which is transferable between staphylococci . Interaction with Other Antimicrobial Drugs In vitro studies have demonstrated additivity or indifference between linezolid and vancomycin, gentamicin, rifampin, imipenem-cilastatin, aztreonam, ampicillin, or streptomycin. Linezolid has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage ( 1 )]. Gram-positive bacteria Enterococcus faecium (vancomycin-resistant isolates only) Staphylococcus aureus (including methicillin-resistant isolates) Streptococcus agalactiae Streptococcus pneumoniae Streptococcus pyogenes The following in vitro data are available, but their clinical significance is unknown. Greater than 90% of the following bacteria exhibit an in vitro MIC less than or equal to the linezolid-susceptible breakpoint for organisms of similar genus. The safety and effectiveness of linezolid in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials. Gram-positive bacteria Enterococcus faecalis (including vancomycin-resistant isolates) Enterococcus faecium (vancomycin-susceptible isolates) Staphylococcus epidermidis (including methicillin-resistant isolates) Staphylococcus haemolyticus Viridans group streptococci Gram-negative bacteria Pasteurella multocida Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["1 INDICATIONS AND USAGE Linezolid for Oral Suspension is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1. 2); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1. 3); Uncomplicated skin and skin structure infections ( 1. 4); Vancomycin-resistant Enterococcus faecium infections. ( 1. 5) Limitations of Use ( 1.6 ): • Linezolid is not indicated for the treatment of Gram-negative infections. • The safety and efficacy of linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials. To reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid formulations and other antibacterial drugs, linezolid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.7 ) 1.1 Nosocomial Pneumonia Linezolid is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae [see Clinical Studies ( 14 )]. 1.2 Community-acquired Pneumonia Linezolid is indicated for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae , including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) [see Clinical Studies ( 14 )]. 1.3 Complicated Skin and Skin Structure Infections Linezolid is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus pyogenes , or Streptococcus agalactiae . Linezolid has not been studied in the treatment of decubitus ulcers [see Clinical Studies ( 14 )]. 1.4 Uncomplicated Skin and Skin Structure Infections Linezolid is indicated for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes [see Clinical Studies ( 14 )]. 1.5 Vancomycin-resistant Enterococcus faecium Infections Linezolid is indicated for the treatment of vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia [see Clinical Studies ( 14 )]. 1.6 Limitations of Use • Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [see Warnings and Precautions ( 5.4 )]. • The safety and efficacy of linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials [see Clinical Studies ( 14 )]. 1.7 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of linezolid and other antibacterial drugs, linezolid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Myelosuppression: Monitor complete blood counts weekly. Thrombocytopenia has been reported more often in patients with severe renal and in patients with moderate to severe hepatic impairment. Consider discontinuation in patients who develop or have worsening myelosuppression. ( 5.1 ) • Peripheral and Optic Neuropathy: Reported primarily in patients treated for longer than 28 days. If patients experience symptoms of visual impairment, prompt ophthalmic evaluation is recommended. ( 5.2 ) • Serotonin Syndrome: Monitor patients taking serotonergic agents, including antidepressants and opioids, for signs of serotonin syndrome. Patients taking serotonergic antidepressants should receive linezolid only if no other therapies are available. Discontinue serotonergic antidepressants and monitor patients for signs and symptoms of both serotonin syndrome and antidepressant discontinuation. ( 5.3 ) • A mortality imbalance was seen in an investigational study in linezolid‑treated patients with catheter-related bloodstream infections. ( 5.4 ) • Clostridioides difficile- Associated Diarrhea: Evaluate if diarrhea occurs. ( 5.5 ) • Potential interactions producing elevation of blood pressure: monitor blood pressure. ( 5.6 ) • Rhabdomyolysis: If signs or symptoms of rhabdomyolysis are observed, discontinue linezolid and initiate appropriate therapy. ( 5.9 ) • Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. ( 5.10 ) • Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Monitor serum sodium levels regularly in patients at risk of hyponatremia and/or SIADH. ( 5.11 ) • Phenylketonuria: Linezolid for Oral Suspension contains phenylalanine which can be harmful to patients with phenylketonuria. ( 5.12 ) 5.1 Myelosuppression Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid was discontinued, the affected hematologic parameters have risen toward pretreatment levels. Thrombocytopenia has been reported more often in patients with severe renal impairment, whether or not on dialysis, and in patients with moderate to severe hepatic impairment. Complete blood counts should be monitored weekly in patients who receive linezolid, particularly in those who receive linezolid for longer than two weeks, those with pre-existing myelosuppression, those with severe renal impairment or moderate to severe hepatic impairment, those receiving concomitant drugs that produce bone marrow suppression, or those with a chronic infection who have received previous or concomitant antibacterial drug therapy. Discontinuation of therapy with linezolid should be considered in patients who develop or have worsening myelosuppression [see Adverse Reactions ( 6.2 )]. 5.2 Peripheral and Optic Neuropathy Peripheral and optic neuropathies have been reported in patients treated with linezolid, primarily in those patients treated for longer than the maximum recommended duration of 28 days. In cases of optic neuropathy that progressed to loss of vision, patients were treated for extended periods beyond the maximum recommended duration. Visual blurring has been reported in some patients treated with linezolid for less than 28 days. Peripheral and optic neuropathy has also been reported in children. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmic evaluation is recommended. Visual function should be monitored in all patients taking linezolid for extended periods (≥ 3 months) and in all patients reporting new visual symptoms regardless of length of therapy with linezolid. If peripheral or optic neuropathy occurs, the continued use of linezolid in these patients should be weighed against the potential risks. 5.3 Serotonin Syndrome Spontaneous reports of serotonin syndrome including fatal cases associated with the co-administration of linezolid and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported. Unless clinically appropriate and patients are carefully observed for signs and/or symptoms of serotonin syndrome or neuroleptic malignant syndrome-like (NMS-like) reactions, linezolid should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin re-uptake inhibitors, tricyclic antidepressants, bupropion, buspirone, serotonin 5-HT1 receptor agonists (triptans), and opioids, including meperidine [see Drug Interactions ( 7 ) and Clinical Pharmacology ( 12.3 )]. In some cases, a patient already receiving a serotonergic antidepressant or buspirone may require urgent treatment with linezolid. If alternatives to linezolid are not available and the potential benefits of linezolid outweigh the risks of serotonin syndrome or NMS-like reactions, the serotonergic antidepressant should be stopped promptly and linezolid administered. The patient should be monitored for two weeks (five weeks if fluoxetine was taken) or until 24 hours after the last dose of linezolid, whichever comes first. Symptoms of serotonin syndrome or NMS-like reactions include hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes that include extreme agitation progressing to delirium and coma. The patient should also be monitored for discontinuation symptoms of the antidepressant (see package insert of the specified agent(s) for a description of the associated discontinuation symptoms). 5.4 Mortality Imbalance in an Investigational Study in Patients with Catheter-Related Bloodstream Infections, Including Those with Catheter-site Infections An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16%); odds ratio 1.426, 95% CI 0.97, 2.098]. While causality has not been established, this observed imbalance occurred primarily in linezolid-treated patients in whom either Gram-negative pathogens, mixed Gram-negative and Gram-positive pathogens, or no pathogen were identified at baseline, but was not seen in patients with Gram-positive infections only. Linezolid is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections. Linezolid has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [see Indications and Usage ( 1 )]. 5.5 Clostridioides difficile- Associated Diarrhea Clostridioides difficile-A ssociated Diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including linezolid, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. 5.6 Potential Interactions Producing Elevation of Blood Pressure Unless patients are monitored for potential increases in blood pressure, linezolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [see Drug Interactions ( 7 ) and Clinical Pharmacology ( 12.3 )] . 5.7 Lactic Acidosis Lactic acidosis has been reported with the use of linezolid. In reported cases, patients experienced repeated episodes of nausea and vomiting. Patients who develop recurrent nausea or vomiting, unexplained acidosis, or a low bicarbonate level while receiving linezolid should receive immediate medical evaluation. 5.8 Convulsions Convulsions have been reported in patients when treated with linezolid. In some of these cases, a history of seizures or risk factors for seizures was reported. 5.9 Rhabdomyolysis Rhabdomyolysis has been reported with the use of linezolid, including linezolid [see Adverse Reactions ( 6.2 )] . If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine or elevated creatine phosphokinase are observed, discontinue linezolid and initiate appropriate therapy. 5.10 Hypoglycemia Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents when treated with linezolid, a reversible, nonselective MAO inhibitor. Some MAO inhibitors have been associated with hypoglycemic episodes in diabetic patients receiving insulin or hypoglycemic agents. While a causal relationship between linezolid and hypoglycemia has not been established, diabetic patients should be cautioned of potential hypoglycemic reactions when treated with linezolid. If hypoglycemia occurs, a decrease in the dose of insulin or oral hypoglycemic agent, or discontinuation of oral hypoglycemic agent, insulin, or linezolid may be required. 5.11 Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Postmarketing cases of hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) have been observed in patients treated with linezolid. In reported cases, the signs and symptoms included confusion, somnolence, generalized weakness, and in severe cases led to respiratory failure and even death. Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking linezolid. If signs and symptoms of hyponatremia and/or SIADH occur, discontinue linezolid, and institute appropriate supportive measures. 5.12 Risks in Patients with Phenylketonuria Phenylalanine can be harmful to patients with phenylketonuria (PKU). Linezolid for Oral Suspension contains phenylalanine, a component of aspartame. Each 5 mL of the 100 mg/5 mL oral suspension contains 20 mg of phenylalanine. Before prescribing Linezolid for Oral Suspension to a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including Linezolid for Oral Suspension. 5.13 Development of Drug-Resistant Bacteria Prescribing linezolid in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria."],"clinical_studies_table":["
Table 12. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with Nosocomial Pneumonia
Cured
PathogenLinezolid n/N (%)Vancomycin n/N (%)
Staphylococcus aureus23/38 (61)14/23 (61)
Methicillin-resistant S. aureus13/22 (59)7/10 (70)
Streptococcus pneumoniae9/9 (100)9/10 (90)
","
Table 13. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with Complicated Skin and Skin Structure Infections
PathogenCured
Linezolidn/N (%)Oxacillin/Dicloxacillinn/N (%)
Staphylococcus aureus73/83 (88)72/84 (86)
Methicillin-resistant S. aureus2/3 (67)0/0 (-)
Streptococcus agalactiae6/6 (100)3/6 (50)
Streptococcus pyogenes18/26 (69)21/28 (75)
","
Table 14. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with Diabetic Foot Infections
PathogenCured
Linezolid n/N (%)Comparator n/N (%)
Staphylococcus aureus49/63 (78)20/29 (69)
Methicillin-resistant S. aureus12/17 (71)2/3 (67)
Streptococcus agalactiae25/29 (86)9/16 (56)
","
Table 15. Cure Rates at the Test-of-Cure Visit for ITT Adult Patients with Documented Vancomycin-Resistant Enterococcal Infections at Baseline
Cured
Source of InfectionLinezolid 600 mg every 12 hours n/N (%)Linezolid200 mg every 12 hours n/N (%)
Any site39/58 (67)24/46 (52)
Any site with associated bacteremia10/17 (59)4/14 (29)
Bacteremia of unknown origin5/10 (50)2/7 (29)
Skin and skin structure9/13 (69)5/5 (100)
Urinary tract12/19 (63)12/20 (60)
Pneumonia2/3 (67)0/1 (0)
OtherIncludes sources of infection such as hepatic abscess, biliary sepsis, necrotic gall bladder, pericolonic abscess, pancreatitis, and catheter-related infection.11/13 (85)5/13 (39)
","
Table 16. Cure Rates at the Test-of-Cure Visit for Intent-to-Treat, Modified Intent-to-Treat, and Clinically Evaluable Pediatric Patients for the Overall Population and by Select Baseline Diagnosis
PopulationITTMITTMIT = ITT patients with an isolated Gram-positive pathogen at baselineClinically Evaluable
Linezolid n/N (%)Vancomycin n/N (%)Linezolid n/N (%)Vancomycin n/N (%)Linezolid n/N (%)Vancomycin n/N (%)
Any diagnosis150/186 (81)69/83 (83)86/108 (80)44/49 (90)106/117 (91)49/54 (91)
Complicated skin and skin structure infections61/72 (85)31/34 (91)37/43 (86)22/23 (96)46/49 (94)26/27 (96)
Nosocomial pneumonia13/18 (72)11/12 (92)5/6 (83)4/4 (100)7/7 (100)5/5 (100)
","
Table 17. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Pediatric Patients with Infections due to Gram-positive Pathogens
PathogenMicrobiologically Evaluable
Linezolidn/N (%)Vancomycinn/N (%)
Vancomycin-resistant Enterococcus faecium 6/8 (75)Includes data from 7 patients enrolled in the open-label extension of this study.0/0 (-)
Staphylococcus aureus36/38 (95)23/24 (96)
Methicillin-resistant S. aureus 16/17 (94)9/9 (100)
Streptococcus pyogenes2/2 (100)1/2 (50)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Lifetime studies in animals have not been conducted to evaluate the carcinogenic potential of linezolid. Neither mutagenic nor clastogenic potential was found in a battery of tests including: assays for mutagenicity (Ames bacterial reversion and CHO cell mutation), an in vitro unscheduled DNA synthesis (UDS) assay, an in vitro chromosome aberration assay in human lymphocytes, and an in vivo mouse micronucleus assay. Linezolid did not affect the fertility or reproductive performance of adult female rats given oral doses of up to 100 mg/kg/day for 14 days prior to mating through Gestation Day 7. It reversibly decreased fertility and reproductive performance in adult male rats when given at doses ≥ 50 mg/kg/day, with exposures approximately equal to or greater than the expected human exposure level (exposure comparisons are based on AUCs). The reversible fertility effects were mediated through altered spermatogenesis. Affected spermatids contained abnormally formed and oriented mitochondria and were non-viable. Epithelial cell hypertrophy and hyperplasia in the epididymis were observed in conjunction with decreased fertility. Similar epididymal changes were not seen in dogs. In sexually mature male rats exposed to drug as juveniles, mildly decreased fertility was observed following treatment with linezolid through most of their period of sexual development (50 mg/kg/day from days 7 to 36 of age, and 100 mg/kg/day from days 37 to 55 of age), with exposures up to 1.7 times greater than mean AUCs observed in pediatric patients aged 3 months to 11 years. Decreased fertility was not observed with shorter treatment periods, corresponding to exposure in utero through the early neonatal period (gestation day 6 through postnatal day 5), neonatal exposure (postnatal days 5 to 21), or to juvenile exposure (postnatal days 22 to 35). Reversible reductions in sperm motility and altered sperm morphology were observed in rats treated from postnatal day 22 to 35. 13.2 Animal Toxicology and/or Pharmacology Target organs of linezolid toxicity were similar in juvenile and adult rats and dogs. Dose- and time-dependent myelosuppression, as evidenced by bone marrow hypocellularity/decreased hematopoiesis, decreased extramedullary hematopoiesis in spleen and liver, and decreased levels of circulating erythrocytes, leukocytes, and platelets have been seen in animal studies. Lymphoid depletion occurred in thymus, lymph nodes, and spleen. Generally, the lymphoid findings were associated with anorexia, weight loss, and suppression of body weight gain, which may have contributed to the observed effects. In rats administered linezolid orally for 6 months, non-reversible, minimal to mild axonal degeneration of sciatic nerves was observed at 80 mg/kg/day; minimal degeneration of the sciatic nerve was also observed in 1 male at this dose level at a 3-month interim necropsy. Sensitive morphologic evaluation of perfusion-fixed tissues was conducted to investigate evidence of optic nerve degeneration. Minimal to moderate optic nerve degeneration was evident in 2 male rats after 6 months of dosing, but the direct relationship to drug was equivocal because of the acute nature of the finding and its asymmetrical distribution. The nerve degeneration observed was microscopically comparable to spontaneous unilateral optic nerve degeneration reported in aging rats and may be an exacerbation of common background change. These effects were observed at exposure levels that are comparable to those observed in some human subjects. The hematopoietic and lymphoid effects were reversible, although in some studies, reversal was incomplete within the duration of the recovery period."],"pharmacokinetics_table":["
Table 8. Mean (Standard Deviation) Pharmacokinetic Parameters of Linezolid in Adults
Dose of LinezolidCmaxmcg/mLCminmcg/mLTmaxhrsAUCAUC for single dose = AUC0-∞; for multiple-dose = AUC0-τmcg • h/mLt1/2hrsCL mL/min
400 mg tablet
single doseData dose-normalized from 375 mg8.10 --- 1.52 55.10 5.20 146
(1.83) (1.01) (25.00) (1.50) (67)
every 12 hours 11.00 3.08 1.12 73.40 4.69 110
(4.37) (2.25) (0.47) (33.50) (1.70) (49)
600 mg tablet
single dose 12.70 --- 1.28 91.40 4.26 127
(3.96) (0.66) (39.30) (1.65) (48)
every 12 hours 21.20 6.15 1.03 138.00 5.40 80
(5.78)(2.94) (0.62) (42.10) (2.06) (29)
600 mg IV injectionData dose-normalized from 625 mg, intravenous dose was given as 0.5-hour infusion. Cmax = Maximum plasma concentration; Cmin = Minimum plasma concentration; Tmax = Time to Cmax; AUC = Area under concentration-time curve; t1/2 = Elimination half-life; CL = Systemic clearance
single dose 12.90 --- 0.5080.20 4.40 138
(1.60) (0.10) (33.30) (2.40) (39)
every 12 hours 15.10 3.68 0.51 89.70 4.80 123
(2.52) (2.36) (0.03) (31.00) (1.70) (40)
600 mg oral suspension
single dose 11.00 --- 0.97 80.80 4.60 141
(2.76) (0.88) (35.10) (1.71) (45)
","
Table 9. Pharmacokinetic Parameters of Linezolid in Pediatrics and Adults Following a Single Intravenous Infusion of 10 mg/kg or 600 mg Linezolid (Mean: (%CV); [Min, Max Values])
Age GroupCmaxmcg/mLVss L/kgAUCAUC = Single dose AUC0-∞ ** In this data set, “pre-term” is defined as <34 weeks gestational age (Note: Only 1 patient enrolled was pre-term with a postnatal age between 1 week and 28 days) ***In this data set, “full-term” is defined as ≥34 weeks gestational age mcg ● h/mLt1/2hrsCL mL/min/kg
Neonatal PatientsPre-term ˂ 1 week (N=9)Dose of 10 mg/kg12.7 (30%) [9.6, 22.2]0.81 (24%) [0.43, 1.05]108 (47%) [41, 191]5.6 (46%) [2.4, 9.8]2.0 (52%) [0.9, 4.0]
Full-term*** < 1 week (N=10)11.5 (24%) [8.0, 18.3] 0.78 (20%) [0.45, 0.96] 55 (47%) [19, 103] 3.0 (55%) [1.3, 6.1] 3.8 (55%) [1.5, 8.8]
Full-term*** ≥ 1 week to ≤ 28 days (N=10)12.9 (28%) [7.7, 21.6] 0.66 (29%) [0.35, 1.06] 34 (21%) [23, 50] 1.5 (17%) [1.2, 1.9] 5.1 (22%) [3.3, 7.2]
Infant Patients > 28 days to < 3 Months (N=12)11.0 (27%) [7.2, 18.0] 0.79 (26%) [0.42, 1.08] 33 (26%) [17, 48] 1.8 (28%) [1.2, 2.8] 5.4 (32%) [3.5, 9.9]
Pediatric Patients 3 months through 11 years (N=59) 15.1 (30%) [6.8, 36.7] 0.69 (28%) [0.31, 1.50] 58 (54%) [19, 153] 2.9 (53%) [0.9, 8.0] 3.8 (53%) [1.0, 8.5]
Adolescent Subjects and Patients 12 through 17 yearsDose of 600 mg or 10 mg/kg up to a maximum of 600 mg(N=36) 16.7 (24%) [9.9, 28.9] 0.61 (15%) [0.44, 0.79] 95 (44%) [32, 178] 4.1 (46%) [1.3, 8.1] 2.1 (53%) [0.9, 5.2]
Adult SubjectsDose normalized to 600 mg Cmax =Maximum plasma concentration; Vss= Volume of distribution; AUC = Area under concentration-time curve; t1/2 =Apparent elimination half-life; CL = Systemic clearance normalized for body weight (N= 29)12.5 (21%) [8.2, 19.3] 0.65 (16%) [0.45, 0.84] 91 (33%) [53, 155] 4.9 (35%) [1.8, 8.3] 1.7 (34%) [0.9, 3.3]
","
Table 10. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Patients with Varying Degrees of Renal Impairment After a Single 600 mg Oral Dose of Linezolid
ParameterHealthy SubjectsCLCR > 80 mL/minModerate Renal Impairment 30 < CLCR < 80 mL/minSevere Renal Impairment 10 < CLCR < 30 mL/min
LINEZOLID
AUC0-∞, mcg h/mL110 (22)128 (53)127 (66)
t1/2, hours6.4 (2.2)6.1 (1.7)7.1 (3.7)
METABOLITE A
AUC0-48, mcg h/mL7.6 (1.9)11.7 (4.3)56.5 (30.6)
t1/2, hours6.3 (2.1)6.6 (2.3)9.0 (4.6)
METABOLITE BMetabolite B is the major metabolite of linezolid.
AUC0-48, mcg h/mL 30.5 (6.2)51.1 (38.5)203 (92)
t1/2, hours 6.6 (2.7)9.9 (7.4)11.0 (3.9)
","
Table 11. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Subjects with End-Stage Renal Disease (ESRD) After the Administration of 600 mg Linezolid Every 12 Hours for 14.5 Days
ParameterESRD SubjectsBetween hemodialysis sessions.
LINEZOLID
AUC0-12, mcg h/mL (after last dose)181 (52.3)
t1/2, h (after last dose)8.3 (2.4)
METABOLITE A
AUC0-12, mcg h/mL (after last dose)153 (40.6)
t1/2, h (after last dose)15.9 (8.5)
METABOLITE BMetabolite B is the major metabolite of linezolid.
AUC0-12, mcg h/mL (after last dose)356 (99.7)
t1/2, h (after last dose)34.8 (23.1)
"],"adverse_reactions_table":["
Table 2. Incidence (%) of Treatment-Emergent Adverse Reactions Occurring in >1% of Adult Patients Treated with Linezolid in Comparator-Controlled Clinical Trials
Uncomplicated Skin and Skin Structure InfectionsAll Other Indications
ADVERSE REACTIONSLinezolid 400 mg by mouth every 12 hours (n=548)Clarithromycin 250 mg by mouth every 12 hours (n=537)Linezolid 600 mg every 12 hours (n=1498)All Other ComparatorsComparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12 hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours. (n=1464)
Headache8.88.45.74.4
Diarrhea8.26.18.36.4
Nausea5.14.56.64.6
Vomiting2.01.54.32.3
Dizziness2.63.01.81.5
Rash1.11.12.32.6
Anemia0.402.11.4
Taste alteration1.82.01.00.3
Vaginal moniliasis1.81.31.10.5
Oral moniliasis0.501.71.0
Abnormal liver function tests0.40.21.60.8
Fungal infection1.50.20.30.2
Tongue discoloration1.300.30
Localized abdominal pain1.30.61.20.8
Generalized abdominal pain0.90.41.21.0
","
Table 3. Incidence (%) of Treatment-Emergent Adverse Reactions Occurring in >1% of Pediatric Patients (and >1 Patient) in Either Treatment Group in Comparator-Controlled Clinical Trials
ADVERSE REACTIONSUncomplicated Skin and Skin Structure InfectionsPatients 5 through 11 years of age received linezolid 10 mg/kg by mouth every 12 hours or cefadroxil 15 mg/kg by mouth every 12 hours. Patients 12 years or older received linezolid 600 mg by mouth every 12 hours or cefadroxil 500 mg by mouth every 12 hours.All Other IndicationsPatients from birth through 11 years of age received linezolid 10 mg/kg intravenously or by mouth every 8 hours or vancomycin 10 to 15 mg/kg intravenously every 6 to 24 hours, depending on age and renal clearance.
Linezolid (n=248) Cefadroxil (n=251) Linezolid (n=215) Vancomycin (n=101)
Diarrhea 7.88.010.812.1
Vomiting2.96.49.49.1
Headache 6.54.00.90
Anemia005.67.1
Thrombocytopenia 004.72.0
Nausea3.73.21.90
Generalized abdominal pain 2.42.80.92.0
Localized abdominal pain 2.42.80.51.0
Loose stools1.60.82.33.0
Eosinophilia 0.40.81.91.0
Pruritus at non-application site0.80.41.42.0
Vertigo1.20.400
","
Table 4. Percent of Adult Patients who Experienced at Least One Substantially Abnormal<75% (<50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; <75% (<50% for neutrophils) of LLN and of baseline for values abnormal at baseline. Hematology Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid
Laboratory AssayUncomplicated Skin and Skin Structure InfectionsAll Other Indications
Linezolid 400 mg every 12 hoursClarithromycin 250 mg every 12 hoursLinezolid 600 mg every 12 hoursAll Other ComparatorsComparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12 hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours.
Hemoglobin (g/dL)0.90.07.16.6
Platelet count (x 103/mm3)0.70.83.01.8
WBC (x 103/mm3)0.20.62.21.3
Neutrophils (x 103/mm3)0.00.21.11.2
","
Table 5. Percent of Adult Patients who Experienced at Least One Substantially Abnormal>2 x Upper Limit of Normal (ULN) for values normal at baseline; >2 x ULN and >2 x baseline for values abnormal at baseline. Serum Chemistry Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid
Laboratory AssayUncomplicated Skin and Skin Structure InfectionsAll Other Indications
Linezolid 400 mg every 12 hoursClarithromycin 250 mg every 12 hoursLinezolid 600 mg every 12 hoursAll Other ComparatorsComparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12 hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours.
AST (U/L)1.71.35.06.8
ALT (U/L)1.71.79.69.3
LDH (U/L)0.20.21.81.5
Alkaline phosphatase (U/L)0.20.23.53.1
Lipase (U/L)2.82.64.34.2
Amylase (U/L)0.20.22.42.0
Total bilirubin (mg/dL)0.20.00.91.1
BUN (mg/dL)0.20.02.11.5
Creatinine (mg/dL)0.20.00.20.6
","
Table 6. Percent of Pediatric Patients who Experienced at Least One Substantially Abnormal<75% (<50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; <75% (<50% for neutrophils) of LLN and <75% (<50% for neutrophils, <90% for hemoglobin if baseline <LLN) of baseline for values abnormal at baseline. Hematology Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid
Laboratory AssayUncomplicated Skin and Skin Structure InfectionsPatients 5 through 11 years of age received linezolid 10 mg/kg by mouth every 12 hours or cefadroxil 15 mg/kg by mouth every 12 hours. Patients 12 years or older received linezolid 600 mg by mouth every 12 hours or cefadroxil 500 mg by mouth every 12 hours.All Other IndicationsPatients from birth through 11 years of age received linezolid 10 mg/kg intravenously or by mouth every 8 hours or vancomycin 10 to 15 mg/kg intravenously every 6-24 hours, depending on age and renal clearance.
LinezolidCefadroxilLinezolidVancomycin
Hemoglobin (g/dL)0.00.015.712.4
Platelet count (x 103/mm3)0.00.412.913.4
WBC (x 103/mm3)0.80.812.410.3
Neutrophils (x 103/mm3)1.20.85.94.3
","
Table 7. Percent of Pediatric Patients who Experienced at Least One Substantially Abnormal>2 x Upper Limit of Normal (ULN) for values normal at baseline; >2 x ULN and >2 (>1.5 for total bilirubin) x baseline for values abnormal at baseline. Serum Chemistry Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid
Laboratory AssayUncomplicated Skin and Skin Structure InfectionsPatients 5 through 11 years of age received linezolid 10 mg/kg by mouth every 12 hours or cefadroxil 15 mg/kg by mouth every 12 hours. Patients 12 years or older received linezolid 600 mg by mouth every 12 hours or cefadroxil 500 mg by mouth every 12 hours.All Other IndicationsPatients from birth through 11 years of age received linezolid 10 mg/kg intravenously or by mouth every 8 hours or vancomycin 10 to 15 mg/kg intravenously every 6-24 hours, depending on age and renal clearance.
LinezolidCefadroxilLinezolidVancomycin
ALT (U/L)0.00.010.112.5
Lipase (U/L)0.41.2------
Amylase (U/L)------0.61.3
Total bilirubin (mg/dL)------6.35.2
Creatinine (mg/dL)0.40.02.41.0
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Important Administration Instructions Advise patients that linezolid may be taken with or without food. Peripheral and Optic Neuropathy Advise patients to inform their physician if they experience changes in vision while taking linezolid [see Warnings and Precautions ( 5.2 )]. Serotonin Syndrome Advise patients to inform their physician if taking serotonergic agents, including serotonin re-uptake inhibitors or other antidepressants and opioids [see Warnings and Precautions ( 5.3 )]. Potential Interactions Producing Elevation of Blood Pressure • Advise patients to inform their physician if they have a history of hypertension. • Advise patients to avoid large quantities of foods or beverages with high tyramine content while taking linezolid. Foods high in tyramine content include those that may have undergone protein changes by aging, fermentation, pickling, or smoking to improve flavor, such as aged cheeses, fermented or air-dried meats, sauerkraut, soy sauce, tap beers, and red wines. The tyramine content of any protein-rich food may be increased if stored for long periods or improperly refrigerated. • Advise patients to inform their physician if taking medications containing pseudoephedrine HCl or phenylpropanolamine HCl, such as cold remedies and decongestants [see Warnings and Precautions ( 5.6 )]. Lactic Acidosis Advise patients to inform their physician if they experience repeated episodes of nausea or vomiting while receiving linezolid [see Warnings and Precautions ( 5.7 )]. Convulsions Advise patients to inform their physician if they have a history of seizures or convulsions [see Warnings and Precautions ( 5.8 )]. Rhabdomyolysis Advise patients to inform their physician if they experience signs and symptoms of rhabdomyolysis including muscle pain, tenderness or weakness and dark urine [see Warnings and Precautions ( 5.9 )]. Hypoglycemia Advise patients to inform their physician if they have diabetes mellitus. Hypoglycemic reactions, such as diaphoresis and tremulousness, along with low blood glucose measurements may occur when treated with linezolid. If such reactions occur, patients should contact a physician or other health professional for proper treatment [see Warnings and Precautions ( 5.10 )]. Hyponatremia and/or SIADH Advise patients at risk for hyponatremia to inform their physician if they experience signs and symptoms of hyponatremia and/or SIADH, including confusion, somnolence, generalized weakness, and respiratory distress [see Warnings and Precautions ( 5.11 )]. Phenylketonuria Advise patients with phenylketonuria (PKU) that each 5 mL of the 100 mg/5 mL linezolid for Oral Suspension contains 20 mg phenylalanine. The other linezolid formulations do not contain phenylalanine. Phenylalanine can be harmful to patients with phenylketonuria. Contact your physician or pharmacist when prescribed with linezolid for Oral Suspension [see Warnings and Precautions ( 5.12 )]. Antibacterial Resistance Patients should be counseled that antibacterial drugs including linezolid should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When linezolid is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by linezolid or other antibacterial drugs in the future. Diarrhea Diarrhea is a common problem caused by antibacterial drugs, which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible [see Warnings and Precautions ( 5.5 )]. Infertility Advise male patients that linezolid may reversibly impair fertility [see Use in Specific Populations ( 8.3 )]. Distributed by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 C50000712/04 Revised July 2024"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Dosage, Route, and Frequency of Administration Infection Pediatric Patients (Birth through 11 years of age) Adults and Adolescents (12 years and older) Duration (Days) Nosocomial pneumonia Community-acquired pneumonia, including concurrent bacteremia 10 mg/kg intravenous or oral every 8 hours 600 mg intravenous or oral every 12 hours 10 to 14 Complicated skin and skin structure infections Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia 10 mg/kg intravenous or oral every 8 hours 600 mg intravenous or oral every 12 hours 14 to 28 Uncomplicated skin and skin structure infections less than 5 yrs: 10 mg/kg oral every 8 hours 5 to 11 yrs: 10 mg/kg oral every 12 hours Adults: 400 mg oral every 12 hours Adolescents: 600 mg oral every 12 hours 10 to 14 2.1 General Dosage and Administration The recommended dosage for linezolid formulations for the treatment of infections is described in Table 1. Table 1. Dosage Guidelines for Linezolid Infection Due to the designated pathogens [see Indications and Usage ( 1 )]. Dosage, Route, and Frequency of Administration Recommended Duration of Treatment (Consecutive Days) Pediatric Patients Neonates less than 7 days: Most pre-term neonates less than 7 days of age (gestational age less than 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg every 8 hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg every 8 hours by 7 days of life [see Use in Specific Populations ( 8.4 ) and Clinical Pharmacology ( 12.3 )]. (Birth through 11 Years of Age) Adults and Adolescents (12 Years and Older) Nosocomial pneumonia 10 mg/kg intravenously or oral Oral dosing using either linezolid tablets or Linezolid for Oral Suspension [see How Supplied/Storage and Handling ( 16 )]. every 8 hours 600 mg intravenously or oral every 12 hours 10 to 14 Community-acquired pneumonia, including concurrent bacteremia Complicated skin and skin structure infections Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia 10 mg/kg intravenously or oral every 8 hours 600 mg intravenously or oral every 12 hours 14 to 28 Uncomplicated skin and skin structure infections Less than 5 yrs: 10 mg/kg oral every 8 hours 5 to 11 yrs: 10 mg/kg oral every 12 hours Adults: 400 mg oral every 12 hours Adolescents: 600 mg oral every 12 hours 10 to 14 No dose adjustment is necessary when switching from intravenous to oral administration. 2.5 Constitution of Oral Suspension Linezolid for Oral Suspension is supplied as a powder for constitution. Gently tap bottle to loosen powder. Add a total of 123 mL distilled water in two portions. After adding the first half, shake vigorously to wet all of the powder. Then add the second half of the water and shake vigorously to obtain a uniform suspension. After constitution, each 5 mL of the suspension contains 100 mg of linezolid. Before using, gently mix by inverting the bottle 3 to 5 times. Do not shake . Store constituted suspension at room temperature. Use within 21 days after constitution."],"spl_product_data_elements":["Linezolid linezolid LINEZOLID LINEZOLID ASPARTAME CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED MICROCRYSTALLINE CELLULOSE ANHYDROUS CITRIC ACID SILICON DIOXIDE MANNITOL SODIUM BENZOATE SODIUM CHLORIDE SODIUM CITRATE, UNSPECIFIED FORM SUCROSE XANTHAN GUM HYPROMELLOSE 2910 (5 MPA.S)"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Linezolid for Oral Suspension: dry, white to tan, orange-flavored powder. When constituted as directed, each bottle will contain 150 mL of a suspension providing the equivalent of 100 mg of linezolid per each 5 mL. • For oral suspension: 100 mg of linezolid per each 5 mL. ( 3 )"],"recent_major_changes_table":["
Warnings and Precautions, Myelosuppression (5.1)Warnings and Precautions, Rhabdomyolysis (5.9) 7/2023 6/2024
"],"clinical_pharmacology_table":["
Table 8. Mean (Standard Deviation) Pharmacokinetic Parameters of Linezolid in Adults
Dose of LinezolidCmaxmcg/mLCminmcg/mLTmaxhrsAUCAUC for single dose = AUC0-∞; for multiple-dose = AUC0-τmcg • h/mLt1/2hrsCL mL/min
400 mg tablet
single doseData dose-normalized from 375 mg8.10 --- 1.52 55.10 5.20 146
(1.83) (1.01) (25.00) (1.50) (67)
every 12 hours 11.00 3.08 1.12 73.40 4.69 110
(4.37) (2.25) (0.47) (33.50) (1.70) (49)
600 mg tablet
single dose 12.70 --- 1.28 91.40 4.26 127
(3.96) (0.66) (39.30) (1.65) (48)
every 12 hours 21.20 6.15 1.03 138.00 5.40 80
(5.78)(2.94) (0.62) (42.10) (2.06) (29)
600 mg IV injectionData dose-normalized from 625 mg, intravenous dose was given as 0.5-hour infusion. Cmax = Maximum plasma concentration; Cmin = Minimum plasma concentration; Tmax = Time to Cmax; AUC = Area under concentration-time curve; t1/2 = Elimination half-life; CL = Systemic clearance
single dose 12.90 --- 0.5080.20 4.40 138
(1.60) (0.10) (33.30) (2.40) (39)
every 12 hours 15.10 3.68 0.51 89.70 4.80 123
(2.52) (2.36) (0.03) (31.00) (1.70) (40)
600 mg oral suspension
single dose 11.00 --- 0.97 80.80 4.60 141
(2.76) (0.88) (35.10) (1.71) (45)
","
Table 9. Pharmacokinetic Parameters of Linezolid in Pediatrics and Adults Following a Single Intravenous Infusion of 10 mg/kg or 600 mg Linezolid (Mean: (%CV); [Min, Max Values])
Age GroupCmaxmcg/mLVss L/kgAUCAUC = Single dose AUC0-∞ ** In this data set, “pre-term” is defined as <34 weeks gestational age (Note: Only 1 patient enrolled was pre-term with a postnatal age between 1 week and 28 days) ***In this data set, “full-term” is defined as ≥34 weeks gestational age mcg ● h/mLt1/2hrsCL mL/min/kg
Neonatal PatientsPre-term ˂ 1 week (N=9)Dose of 10 mg/kg12.7 (30%) [9.6, 22.2]0.81 (24%) [0.43, 1.05]108 (47%) [41, 191]5.6 (46%) [2.4, 9.8]2.0 (52%) [0.9, 4.0]
Full-term*** < 1 week (N=10)11.5 (24%) [8.0, 18.3] 0.78 (20%) [0.45, 0.96] 55 (47%) [19, 103] 3.0 (55%) [1.3, 6.1] 3.8 (55%) [1.5, 8.8]
Full-term*** ≥ 1 week to ≤ 28 days (N=10)12.9 (28%) [7.7, 21.6] 0.66 (29%) [0.35, 1.06] 34 (21%) [23, 50] 1.5 (17%) [1.2, 1.9] 5.1 (22%) [3.3, 7.2]
Infant Patients > 28 days to < 3 Months (N=12)11.0 (27%) [7.2, 18.0] 0.79 (26%) [0.42, 1.08] 33 (26%) [17, 48] 1.8 (28%) [1.2, 2.8] 5.4 (32%) [3.5, 9.9]
Pediatric Patients 3 months through 11 years (N=59) 15.1 (30%) [6.8, 36.7] 0.69 (28%) [0.31, 1.50] 58 (54%) [19, 153] 2.9 (53%) [0.9, 8.0] 3.8 (53%) [1.0, 8.5]
Adolescent Subjects and Patients 12 through 17 yearsDose of 600 mg or 10 mg/kg up to a maximum of 600 mg(N=36) 16.7 (24%) [9.9, 28.9] 0.61 (15%) [0.44, 0.79] 95 (44%) [32, 178] 4.1 (46%) [1.3, 8.1] 2.1 (53%) [0.9, 5.2]
Adult SubjectsDose normalized to 600 mg Cmax =Maximum plasma concentration; Vss= Volume of distribution; AUC = Area under concentration-time curve; t1/2 =Apparent elimination half-life; CL = Systemic clearance normalized for body weight (N= 29)12.5 (21%) [8.2, 19.3] 0.65 (16%) [0.45, 0.84] 91 (33%) [53, 155] 4.9 (35%) [1.8, 8.3] 1.7 (34%) [0.9, 3.3]
","
Table 10. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Patients with Varying Degrees of Renal Impairment After a Single 600 mg Oral Dose of Linezolid
ParameterHealthy SubjectsCLCR > 80 mL/minModerate Renal Impairment 30 < CLCR < 80 mL/minSevere Renal Impairment 10 < CLCR < 30 mL/min
LINEZOLID
AUC0-∞, mcg h/mL110 (22)128 (53)127 (66)
t1/2, hours6.4 (2.2)6.1 (1.7)7.1 (3.7)
METABOLITE A
AUC0-48, mcg h/mL7.6 (1.9)11.7 (4.3)56.5 (30.6)
t1/2, hours6.3 (2.1)6.6 (2.3)9.0 (4.6)
METABOLITE BMetabolite B is the major metabolite of linezolid.
AUC0-48, mcg h/mL 30.5 (6.2)51.1 (38.5)203 (92)
t1/2, hours 6.6 (2.7)9.9 (7.4)11.0 (3.9)
","
Table 11. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Subjects with End-Stage Renal Disease (ESRD) After the Administration of 600 mg Linezolid Every 12 Hours for 14.5 Days
ParameterESRD SubjectsBetween hemodialysis sessions.
LINEZOLID
AUC0-12, mcg h/mL (after last dose)181 (52.3)
t1/2, h (after last dose)8.3 (2.4)
METABOLITE A
AUC0-12, mcg h/mL (after last dose)153 (40.6)
t1/2, h (after last dose)15.9 (8.5)
METABOLITE BMetabolite B is the major metabolite of linezolid.
AUC0-12, mcg h/mL (after last dose)356 (99.7)
t1/2, h (after last dose)34.8 (23.1)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary Available data from published and postmarketing case reports with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. When administered during organogenesis, linezolid did not cause malformations in mice, rats, or rabbits at maternal exposure levels approximately 6.5 times (mice), equivalent to (rats), or 0.06 times (rabbits) the clinical therapeutic exposure, based on AUCs. However, embryo-fetal lethality was observed in mice at 6.5 times the estimated human exposure. When female rats were dosed during organogenesis through lactation, postnatal survival of pups was decreased at doses approximately equivalent to the estimated human exposure based on AUCs ( see Data ) . The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data : In mice, embryo-fetal toxicities were observed only at doses that caused maternal toxicity (clinical signs and reduced body weight gain). An oral dose of 450 mg/kg/day given from Gestation Day (GD) 6-16 (6.5 times the estimated human exposure based on AUCs) correlated with increased postimplantational embryo death, including total litter loss, decreased fetal body weights, and an increased incidence of costal cartilage fusion. Neither maternal nor embryo-fetal toxicities were observed at doses up to 150 mg/kg/day. Fetal malformations were not observed. In rats, fetal toxicity was observed at 15 and 50 mg/kg/day administered orally from GD 6-17 (exposures 0.22 times to approximately equivalent to the estimated human exposure, respectively, based on AUCs). The effects consisted of decreased fetal body weights and reduced ossification of sternebrae, a finding often seen in association with decreased fetal body weights. Fetal malformations were not observed. Maternal toxicity, in the form of reduced body weight gain, was seen at 50 mg/kg/day. In rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) when administered at an oral dose of 15 mg/kg/day given from GD 6-20 (0.06 times the estimated human exposure based on AUCs). Fetal malformations were not observed. When female rats were treated with 50 mg/kg/day (approximately equivalent to the estimated human exposure based on AUCs) of linezolid during pregnancy and lactation, (GD 6 through Lactation Day 20), survival of pups was decreased on postnatal days 1 to 4. Male and female pups permitted to mature to reproductive age, when mated, showed an increase in preimplantation loss. 8.2 Lactation Risk Summary Linezolid is present in breast milk. Based on data from available published case reports, the daily dose of linezolid that the infant would receive from breastmilk would be approximately 6% to 9% of the recommended therapeutic infant dose (10 mg/kg every 8 hours). There is no information on the effects of linezolid on the breastfed infant; however, diarrhea and vomiting were the most common adverse reactions reported in clinical trials in infants receiving linezolid therapeutically [see Adverse Reactions ( 6.1 )] and (see Clinical Considerations). There is no information on the effects of linezolid on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for linezolid and any potential adverse effects on the breastfed child from linezolid or from the underlying maternal condition. Clinical Considerations Advise lactating women to monitor a breastfed infant for diarrhea and vomiting. 8.3 Females and Males of Reproductive Potential Infertility Males: Based on findings from studies in rats, linezolid may reversibly impair fertility in male patients [see Nonclinical Toxicology ( 13.1 )]. 8.4 Pediatric Use The safety and effectiveness of linezolid for the treatment of pediatric patients with the following infections are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from a comparator-controlled study of Gram-positive infections in pediatric patients ranging in age from birth through 11 years [see Indications and Usage ( 1 ), Clinical Pharmacology ( 12.3 ) and Clinical Studies ( 14 )]: • nosocomial pneumonia • complicated skin and skin structure infections • community-acquired pneumonia (also supported by evidence from an uncontrolled study in patients ranging in age from 8 months through 12 years) • vancomycin-resistant Enterococcus faecium infections The safety and effectiveness of linezolid for the treatment of pediatric patients with the following infection have been established in a comparator-controlled study in pediatric patients ranging in age from 5 through 17 years [see Clinical Studies ( 14 )]: • uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes Pharmacokinetic information generated in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) linezolid concentrations following single and multiple dosing of linezolid; therapeutic concentrations were not consistently achieved or maintained in the CSF. Therefore, the use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended. The pharmacokinetics of linezolid have been evaluated in pediatric patients from birth to 17 years of age. In general, weight-based clearance of linezolid gradually decreases with increasing age of pediatric patients. However, in preterm (gestational age < 34 weeks) neonates < 7 days of age, linezolid clearance is often lower than in full-term neonates < 7 days of age. Consequently, preterm neonates < 7 days of age may need an alternative linezolid dosing regimen of 10 mg/kg every 12 hours [see Dosage and Administration ( 2.1 ) and Clinical Pharmacology ( 12.3 )]. In limited clinical experience, 5 out of 6 (83%) pediatric patients with infections due to Gram-positive pathogens with minimum inhibitory concentrations (MICs) of 4 mcg/mL treated with linezolid had clinical cures. However, pediatric patients exhibit wider variability in linezolid clearance and systemic exposure (AUC) compared with adults. In pediatric patients with a sub-optimal clinical response, particularly those with pathogens with MIC of 4 mcg/mL, lower systemic exposure, site and severity of infection, and the underlying medical condition should be considered when assessing clinical response [see Clinical Pharmacology ( 12.3 ) and Dosage and Administration ( 2 )]. 8.5 Geriatric Use Of the 2,046 patients treated with linezolid in Phase 3 comparator-controlled clinical trials, 589 (29%) were 65 years or older and 253 (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"dosage_and_administration_table":["
Dosage, Route, and Frequency of Administration
InfectionPediatric Patients(Birth through 11 years of age)Adults and Adolescents(12 years and older)Duration(Days)
Nosocomial pneumonia
Community-acquired pneumonia, including concurrent bacteremia10 mg/kgintravenous or oralevery 8 hours600 mgintravenous or oralevery 12 hours10 to 14
Complicated skin and skin structure infections
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia10 mg/kgintravenous or oralevery 8 hours600 mgintravenous or oralevery 12 hours14 to 28
Uncomplicated skin and skin structure infectionsless than 5 yrs: 10 mg/kg oralevery 8 hours5 to 11 yrs: 10 mg/kg oralevery 12 hoursAdults: 400 mg oralevery 12 hoursAdolescents: 600 mg oralevery 12 hours10 to 14
","
Table 1. Dosage Guidelines for Linezolid
InfectionDue to the designated pathogens [see Indications and Usage (1)].Dosage, Route, and Frequency of AdministrationRecommended Duration of Treatment (Consecutive Days)
Pediatric PatientsNeonates less than 7 days: Most pre-term neonates less than 7 days of age (gestational age less than 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg every 8 hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg every 8 hours by 7 days of life [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]. (Birth through 11 Years of Age)Adults and Adolescents (12 Years and Older)
Nosocomial pneumonia10 mg/kg intravenously or oralOral dosing using either linezolid tablets or Linezolid for Oral Suspension [see How Supplied/Storage and Handling (16)]. every 8 hours600 mg intravenously or oral every 12 hours10 to 14
Community-acquired pneumonia, including concurrent bacteremia
Complicated skin and skin structure infections
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia10 mg/kg intravenously or oral every 8 hours600 mg intravenously or oral every 12 hours14 to 28
Uncomplicated skin and skin structure infectionsLess than 5 yrs: 10 mg/kg oral every 8 hours5 to 11 yrs: 10 mg/kg oral every 12 hoursAdults: 400 mg oral every 12 hoursAdolescents: 600 mg oral every 12 hours10 to 14
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Target organs of linezolid toxicity were similar in juvenile and adult rats and dogs. Dose- and time-dependent myelosuppression, as evidenced by bone marrow hypocellularity/decreased hematopoiesis, decreased extramedullary hematopoiesis in spleen and liver, and decreased levels of circulating erythrocytes, leukocytes, and platelets have been seen in animal studies. Lymphoid depletion occurred in thymus, lymph nodes, and spleen. Generally, the lymphoid findings were associated with anorexia, weight loss, and suppression of body weight gain, which may have contributed to the observed effects. In rats administered linezolid orally for 6 months, non-reversible, minimal to mild axonal degeneration of sciatic nerves was observed at 80 mg/kg/day; minimal degeneration of the sciatic nerve was also observed in 1 male at this dose level at a 3-month interim necropsy. Sensitive morphologic evaluation of perfusion-fixed tissues was conducted to investigate evidence of optic nerve degeneration. Minimal to moderate optic nerve degeneration was evident in 2 male rats after 6 months of dosing, but the direct relationship to drug was equivocal because of the acute nature of the finding and its asymmetrical distribution. The nerve degeneration observed was microscopically comparable to spontaneous unilateral optic nerve degeneration reported in aging rats and may be an exacerbation of common background change. These effects were observed at exposure levels that are comparable to those observed in some human subjects. The hematopoietic and lymphoid effects were reversible, although in some studies, reversal was incomplete within the duration of the recovery period."],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL linezolid-for-os-bottle-label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Lifetime studies in animals have not been conducted to evaluate the carcinogenic potential of linezolid. Neither mutagenic nor clastogenic potential was found in a battery of tests including: assays for mutagenicity (Ames bacterial reversion and CHO cell mutation), an in vitro unscheduled DNA synthesis (UDS) assay, an in vitro chromosome aberration assay in human lymphocytes, and an in vivo mouse micronucleus assay. Linezolid did not affect the fertility or reproductive performance of adult female rats given oral doses of up to 100 mg/kg/day for 14 days prior to mating through Gestation Day 7. It reversibly decreased fertility and reproductive performance in adult male rats when given at doses ≥ 50 mg/kg/day, with exposures approximately equal to or greater than the expected human exposure level (exposure comparisons are based on AUCs). The reversible fertility effects were mediated through altered spermatogenesis. Affected spermatids contained abnormally formed and oriented mitochondria and were non-viable. Epithelial cell hypertrophy and hyperplasia in the epididymis were observed in conjunction with decreased fertility. Similar epididymal changes were not seen in dogs. In sexually mature male rats exposed to drug as juveniles, mildly decreased fertility was observed following treatment with linezolid through most of their period of sexual development (50 mg/kg/day from days 7 to 36 of age, and 100 mg/kg/day from days 37 to 55 of age), with exposures up to 1.7 times greater than mean AUCs observed in pediatric patients aged 3 months to 11 years. Decreased fertility was not observed with shorter treatment periods, corresponding to exposure in utero through the early neonatal period (gestation day 6 through postnatal day 5), neonatal exposure (postnatal days 5 to 21), or to juvenile exposure (postnatal days 22 to 35). Reversible reductions in sperm motility and altered sperm morphology were observed in rats treated from postnatal day 22 to 35."]},"tags":[{"label":"Oxazolidinone Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Amine oxidase [flavin-containing] A","category":"target"},{"label":"MAOA","category":"gene"},{"label":"SDHA","category":"gene"},{"label":"MAOB","category":"gene"},{"label":"J01XX08","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Granule","category":"form"},{"label":"Injection","category":"form"},{"label":"Powder","category":"form"},{"label":"Suspension","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Complicated Skin and Skin Structure Staphylococcus Aureus Infection","category":"indication"},{"label":"Complicated Skin and Skin Structure Streptococcus Agalactiae Infection","category":"indication"},{"label":"Complicated Skin and Skin Structure Streptococcus Pyogenes Infection","category":"indication"},{"label":"Diabetic Foot Infection Due to Gram-Positive Bacteria","category":"indication"},{"label":"Infection due to Staphylococcus aureus","category":"indication"},{"label":"Pneumonia due to Streptococcus","category":"indication"},{"label":"Pfizer","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protein Synthesis Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"2427 reports"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"2032 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1994 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"1601 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"1380 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1301 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"1062 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1003 reports"},{"date":"","signal":"PLATELET COUNT DECREASED","source":"FDA FAERS","actionTaken":"1001 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"981 reports"}],"drugInteractions":[{"url":"/drug/bupivacaine","drug":"bupivacaine","action":"Avoid combination","effect":"May interact with Bupivacaine","source":"DrugCentral","drugSlug":"bupivacaine"},{"url":"/drug/desvenlafaxine","drug":"desvenlafaxine","action":"Monitor closely","effect":"May interact with Desvenlafaxine","source":"DrugCentral","drugSlug":"desvenlafaxine"},{"url":"/drug/dextropropoxyphene","drug":"dextropropoxyphene","action":"Avoid combination","effect":"May interact with Propoxyphene","source":"DrugCentral","drugSlug":"dextropropoxyphene"},{"url":"/drug/entacapone","drug":"entacapone","action":"Avoid combination","effect":"May interact with Entacapone","source":"DrugCentral","drugSlug":"entacapone"},{"url":"/drug/lisdexamfetamine","drug":"lisdexamfetamine","action":"Avoid combination","effect":"May interact with Lisdexamfetamine","source":"DrugCentral","drugSlug":"lisdexamfetamine"},{"url":"/drug/maprotiline","drug":"maprotiline","action":"Avoid combination","effect":"May interact with Maprotiline","source":"DrugCentral","drugSlug":"maprotiline"},{"url":"/drug/mepivacaine","drug":"mepivacaine","action":"Avoid combination","effect":"May interact with Mepivacaine","source":"DrugCentral","drugSlug":"mepivacaine"},{"url":"/drug/methadone","drug":"methadone","action":"Avoid combination","effect":"May interact with Methadone","source":"DrugCentral","drugSlug":"methadone"},{"url":"/drug/methylphenidate","drug":"methylphenidate","action":"Avoid combination","effect":"May interact with Methylphenidate","source":"DrugCentral","drugSlug":"methylphenidate"},{"url":"/drug/mirtazapine","drug":"mirtazapine","action":"Monitor closely","effect":"May interact with Mirtazapine","source":"DrugCentral","drugSlug":"mirtazapine"},{"url":"/drug/naratriptan","drug":"naratriptan","action":"Avoid combination","effect":"May interact with Naratriptan Hydrochloride","source":"DrugCentral","drugSlug":"naratriptan"},{"url":"/drug/nefazodone","drug":"nefazodone","action":"Avoid combination","effect":"May interact with Nefazodone","source":"DrugCentral","drugSlug":"nefazodone"},{"url":"/drug/norepinephrine","drug":"norepinephrine","action":"Avoid combination","effect":"May interact with Norepinephrine","source":"DrugCentral","drugSlug":"norepinephrine"},{"url":"/drug/nortriptyline","drug":"nortriptyline","action":"Avoid combination","effect":"May interact with Nortriptyline","source":"DrugCentral","drugSlug":"nortriptyline"},{"url":"/drug/oxycodone","drug":"oxycodone","action":"Avoid combination","effect":"May interact with Oxycodone","source":"DrugCentral","drugSlug":"oxycodone"},{"url":"/drug/pethidine","drug":"pethidine","action":"Avoid combination","effect":"May interact with Meperidine","source":"DrugCentral","drugSlug":"pethidine"},{"url":"/drug/phenelzine","drug":"phenelzine","action":"Avoid combination","effect":"May interact with Phenelzine","source":"DrugCentral","drugSlug":"phenelzine"},{"url":"/drug/phenylpropanolamine","drug":"phenylpropanolamine","action":"Avoid combination","effect":"May interact with Phenylpropanolamine","source":"DrugCentral","drugSlug":"phenylpropanolamine"},{"url":"/drug/procaine","drug":"procaine","action":"Avoid combination","effect":"May interact with Procaine","source":"DrugCentral","drugSlug":"procaine"},{"url":"/drug/protriptyline","drug":"protriptyline","action":"Monitor closely","effect":"May interact with Protriptyline","source":"DrugCentral","drugSlug":"protriptyline"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"8.3%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"6.5%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"6.2%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"3.7%","severity":"mild","_validated":true},{"effect":"Insomnia","drugRate":"2.5%","severity":"mild","_validated":true},{"effect":"Constipation","drugRate":"2.2%","severity":"mild","_validated":true},{"effect":"Rash","drugRate":"2.0%","severity":"mild","_validated":true},{"effect":"Dizziness","drugRate":"2.0%","severity":"mild","_validated":true},{"effect":"Fever","drugRate":"1.6%","severity":"mild","_validated":true},{"effect":"Fungal infection","drugRate":"1.5%","severity":"mild","_validated":true},{"effect":"Abnormal liver function tests","drugRate":"0.4%","severity":"mild","_validated":true},{"effect":"Tongue discoloration","drugRate":"1.1%","severity":"mild","_validated":true},{"effect":"Vaginal moniliasis","drugRate":"1.6%","severity":"mild","_validated":true},{"effect":"Oral moniliasis","drugRate":"0.4%","severity":"mild","_validated":true},{"effect":"Anemia","drugRate":"0.0%","severity":"mild","_validated":true},{"effect":"Thrombocytopenia","drugRate":"0.0%","severity":"mild","_validated":true},{"effect":"Upper respiratory infection","drugRate":"3.7%","severity":"common","_validated":true},{"effect":"Loose stools","drugRate":"1.6%","severity":"mild","_validated":true},{"effect":"Localized abdominal pain","drugRate":"2.4%","severity":"mild","_validated":true},{"effect":"Generalized abdominal pain","drugRate":"2.4%","severity":"mild","_validated":true},{"effect":"Sepsis","drugRate":"0.0%","severity":"serious","_validated":true}],"contraindications":["Anemia","Bone marrow depression","Carcinoid syndrome","Disorder of optic nerve","Hypertensive disorder","Lactic acidosis","Leukopenia","Pancytopenia","Peripheral nerve disease","Pheochromocytoma","Pseudomembranous enterocolitis","Seizure disorder","Serotonin syndrome","Thrombocytopenic disorder","Thyrotoxicosis","Visual impairment"],"specialPopulations":{"Pregnancy":"Linezolid was not teratogenic in mice, rats, or rabbits at exposure levels 6.5-fold (in mice), equivalent to (in rats), or 0.06-fold (in rabbits) the expected human exposure level, based on AUCs. However, embryo and fetal toxicities were seen. There are no adequate and well-controlled studies in pregnant women. Linezolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.","Geriatric use":"No overall differences in safety or effectiveness were observed between patients 65 years or older and younger patients.","Paediatric use":"The safety and effectiveness of ZYVOX for the treatment of pediatric patients with the following infections are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from comparator-controlled study of Gram-positive infections in pediatric patients ranging in age from birth through 11 years."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.9512/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$712","description":"LINEZOLID 600 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=linezolid","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:29.104606+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Linezolid","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:37:36.554957+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:34.825141+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:37:25.236025+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=linezolid","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:35.299152+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:22.550754+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:22.550784+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:22.550791+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:37:37.027383+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial 70S ribosome inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:36.554908+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL126/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:36.206275+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA200068","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:22.550795+00:00"}},"allNames":"zyvox","offLabel":[],"synonyms":["linezolid","linospan","linox","zyvox","zyvoxid","linezolid sodium chloride","linezolide","U-100766","U 100766"],"timeline":[{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PHARMACIA AND UPJOHN to Pfizer"},{"date":"2000-04-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pharmacia And Upjohn)"},{"date":"2015-06-18","type":"positive","source":"FDA Orange Book","milestone":"Linezolid In Sodium Chloride 0.9% In Plastic Container approved — 600MG/300ML (2MG/ML)"},{"date":"2019-04-25","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 21 manufacturers approved"}],"aiSummary":"Zyvox (linezolid) is a small molecule oxazolidinone antibacterial drug developed by Pharmacia and Upjohn, now owned by Pfizer. It targets the amine oxidase [flavin-containing] A enzyme and is FDA-approved to treat various infections caused by Gram-positive bacteria, including complicated skin and skin structure infections, diabetic foot infections, and pneumonia. Zyvox is a generic medication with 24 available manufacturers and is no longer patented. Key safety considerations include potential thrombocytopenia and peripheral neuropathy. It has a half-life of 4.5 hours and 99% bioavailability.","brandName":"Zyvox","ecosystem":[{"indication":"Complicated Skin and Skin Structure Staphylococcus Aureus Infection","otherDrugs":[{"name":"dalfopristin","slug":"dalfopristin","company":""},{"name":"daptomycin","slug":"daptomycin","company":"Cubist"},{"name":"ertapenem","slug":"ertapenem","company":"Merck Sharp Dohme"},{"name":"levofloxacin","slug":"levofloxacin","company":"Janssen Pharms"}],"globalPrevalence":null},{"indication":"Complicated Skin and Skin Structure Streptococcus Agalactiae Infection","otherDrugs":[{"name":"daptomycin","slug":"daptomycin","company":"Cubist"},{"name":"norfloxacin","slug":"norfloxacin","company":""},{"name":"telavancin","slug":"telavancin","company":"Theravance Biopharma"},{"name":"tigecycline","slug":"tigecycline","company":"Pf Prism Cv"}],"globalPrevalence":null},{"indication":"Complicated Skin and Skin Structure Streptococcus Pyogenes Infection","otherDrugs":[{"name":"daptomycin","slug":"daptomycin","company":"Cubist"},{"name":"ertapenem","slug":"ertapenem","company":"Merck Sharp Dohme"},{"name":"levofloxacin","slug":"levofloxacin","company":"Janssen Pharms"},{"name":"norfloxacin","slug":"norfloxacin","company":""}],"globalPrevalence":null},{"indication":"Diabetic Foot Infection Due to Gram-Positive Bacteria","otherDrugs":[],"globalPrevalence":null},{"indication":"Infection due to Staphylococcus aureus","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Pneumonia due to Streptococcus","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"benzathine benzylpenicillin","slug":"benzathine-benzylpenicillin","company":"King Pharms"}],"globalPrevalence":null},{"indication":"Staphylococcal pneumonia","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Streptococcus pyogenes infection","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"benzathine benzylpenicillin","slug":"benzathine-benzylpenicillin","company":"King Pharms"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Amine oxidase [flavin-containing] A","novelty":"Follow-on","targets":[{"gene":"MAOA","source":"DrugCentral","target":"Amine oxidase [flavin-containing] A","protein":"Amine oxidase [flavin-containing] A"},{"gene":"SDHA","source":"DrugCentral","target":"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","protein":"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial"},{"gene":"MAOB","source":"DrugCentral","target":"Amine oxidase [flavin-containing] B","protein":"Amine oxidase [flavin-containing] B"}],"modality":"Small Molecule","drugClass":"Oxazolidinone Antibacterial [EPC]","explanation":"ZYVOX is an antibacterial drug see Microbiology (12.4) ].","oneSentence":"Zyvox works by inhibiting the bacterial protein synthesis initiation complex, preventing the growth and replication of Gram-positive bacteria.","technicalDetail":"Zyvox binds to the 50S ribosomal subunit of the bacterial ribosome, inhibiting the action of the 23S rRNA and preventing the formation of the 70S initiation complex, which is essential for protein synthesis initiation in Gram-positive bacteria.","_target_confidence":0.5},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Linezolid","title":"Linezolid","extract":"Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). The main uses are infections of the skin and pneumonia although it may be used for a variety of other infections including drug-resistant tuberculosis. It is used either by injection into a vein or by mouth.","wiki_history":"==History==\nThe oxazolidinones have been known as monoamine oxidase inhibitors since the late 1950s. Their antimicrobial properties were discovered by researchers at E.I. duPont de Nemours in the 1970s. In 1978, DuPont patented a series of oxazolidinone derivatives as being effective in the treatment of bacterial and fungal plant diseases, and in 1984, another patent described their usefulness in treating bacterial infections in mammals. Early compounds were found to produce liver toxicity, however, and development was discontinued.\n\nPharmacia & Upjohn (now part of Pfizer) started its own oxazolidinone research program in the 1990s. Studies of the compounds' structure–activity relationships led to the development of several subclasses of oxazolidinone derivatives, with varying safety profiles and antimicrobial activity. Two compounds were considered drug candidates: eperezolid (codenamed PNU-100592) and linezolid (PNU-100766). Linezolid was found to have a pharmacokinetic advantage—requiring only twice-daily dosage, while eperezolid needed to be given three times a day to achieve similar exposure—and therefore proceeded to further trials. Approval followed in Brazil (June 2000), the United Kingdom (January 2001), Europe (throughout 2001), and other countries in Latin America and Asia. Other members of this class have entered development, such as posizolid (AZD2563), ranbezolid (RBx 7644), and radezolid (RX-1741). In 2014, the FDA approved tedizolid phosphate, a second-generation oxazolidinone derivative, for acute bacterial skin and skin structure infection.","wiki_society_and_culture":"==Society and culture==\n\n===Economics===\n\n\nLinezolid was quite expensive in 2009; a course of treatment may cost one or two thousand U.S. dollars for the drug alone, not to mention other costs (such as those associated with hospital stay). With the medication becoming generic the price has decreased. In India as of 2015 a month of linezolid, as would be used to treat tuberculosis cost about US$60.\n\nIn 2009, Pfizer paid $2.3 billion and entered a corporate integrity agreement to settle charges that it had misbranded and illegally promoted four drugs, and caused false claims to be submitted to government healthcare programs for uses that had not been approved by the United States Food and Drug Administration. $1.3 billion was paid to settle criminal charges of illegally marketing the anti-inflammatory valdecoxib, while $1 billion was paid in civil fines regarding illegal marketing of three other drugs, including Zyvox.\n\n===Brand names===\n{| class=\"wikitable mw-collapsible mw-collapsed\" style=\"width:100%\"\n|+ List of trade names for linezolid\n|-\n|A||Amizole 500 (Kenya), Anozilad (Poland), Antizolid (Greece), Arlid (India), Arlin (Bangladesh), Averozolid & Debacozoline (Egypt)\n|-\n|-\n|B||\n|-\n|C||\n|-\n|D||Dilizolen (Poland, Slovakia, Netherlands, Bulgaria)\n|-\n|E||Entavar (India)\n|-\n|F||\n|-\n|G||Grampolid (Netherlands), Grampolyve (Netherlands), Gramposimide (Poland, Netherlands), Grampoxid (Netherlands)\n|-\n|H||\n|-\n|I||\n|-\n|J||\n|-\n|K||\n|-\n|L||Linzolid (Bangladesh), Lidobact (Netherlands), Linez (Bangladesh, Egypt), Linezolid Accord (Netherlands), Linezolid Amneal (Netherlands), Linezolid Betapharm (Netherlands), Linezolid Farmaprojects (Netherlands), Linezolid Fresenius Kabi (Netherlands), Linezolid GNP (Egypt), Linezolid Hetero (Netherlands), Linezolid Kabi (Croatia, Poland), Linezolid Mylan (Netherlands), Linezolid Pfizer (Netherlands), Linezolid Pliva (Croatia), Linezolid Polpharma (Netherlands, Poland), Linezolid Richet (Argentina), Linezolid Sandoz (Belgiu"},"commercial":{"launchDate":"2000","_launchSource":"DrugCentral (FDA 2000-04-18, PHARMACIA AND UPJOHN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1584","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=linezolid","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=linezolid","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Linezolid","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T02:03:36.933251","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:40.314787+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"fosfomycin","drugSlug":"fosfomycin","fdaApproval":"1996-12-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"spectinomycin","drugSlug":"spectinomycin","fdaApproval":"1971-06-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"methenamine","drugSlug":"methenamine","fdaApproval":"1967-07-05","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"daptomycin","drugSlug":"daptomycin","fdaApproval":"2003-09-12","patentExpiry":"Sep 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"bacitracin","drugSlug":"bacitracin","fdaApproval":"1948-07-29","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tedizolid phosphate","drugSlug":"tedizolid-phosphate","fdaApproval":"2014-06-20","patentExpiry":"Jun 20, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lefamulin","drugSlug":"lefamulin","fdaApproval":"2019-08-19","patentExpiry":"May 23, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"linezolid","indications":{"approved":[{"name":"Complicated Skin and Skin Structure Staphylococcus Aureus Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older"},{"name":"Complicated Skin and Skin Structure Streptococcus Agalactiae Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older"},{"name":"Complicated Skin and Skin Structure Streptococcus Pyogenes Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older"},{"name":"Diabetic Foot Infection Due to Gram-Positive Bacteria","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older, without concomitant osteomyelitis"},{"name":"Infection due to Staphylococcus aureus","source":"DrugCentral","snomedId":406602003,"regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older, methicillin-susceptible strains only"},{"name":"Pneumonia due to Streptococcus","source":"DrugCentral","snomedId":34020007,"regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older, including cases with concurrent bacteremia"},{"name":"Staphylococcal pneumonia","source":"DrugCentral","snomedId":22754005,"regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older, methicillin-susceptible strains only"},{"name":"Streptococcus pyogenes infection","source":"DrugCentral","snomedId":302809008,"regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older"},{"name":"Vancomycin resistant enterococcus","source":"DrugCentral","snomedId":113727004,"regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older"},{"name":"Vancomycin-Resistant Enterococcus Faecium Infection","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and pediatric patients 5 months of age and older, including cases with concurrent bacteremia"}],"offLabel":[{"name":"Infection of bone","source":"DrugCentral","drugName":"linezolid","evidenceCount":361,"evidenceLevel":"strong"},{"name":"Pyrexia of unknown origin","source":"DrugCentral","drugName":"linezolid","evidenceCount":4,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Pfizer","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"fosfomycin","brandName":"fosfomycin","genericName":"fosfomycin","approvalYear":"1996","relationship":"same-class"},{"drugId":"spectinomycin","brandName":"spectinomycin","genericName":"spectinomycin","approvalYear":"1971","relationship":"same-class"},{"drugId":"methenamine","brandName":"methenamine","genericName":"methenamine","approvalYear":"1967","relationship":"same-class"},{"drugId":"daptomycin","brandName":"daptomycin","genericName":"daptomycin","approvalYear":"2003","relationship":"same-class"},{"drugId":"bacitracin","brandName":"bacitracin","genericName":"bacitracin","approvalYear":"1948","relationship":"same-class"},{"drugId":"tedizolid-phosphate","brandName":"tedizolid phosphate","genericName":"tedizolid phosphate","approvalYear":"2014","relationship":"same-class"},{"drugId":"lefamulin","brandName":"lefamulin","genericName":"lefamulin","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06958835","phase":"NA","title":"Linezolid Plus Standard of Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-06","conditions":["Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)"],"enrollment":606,"completionDate":"2028-10"},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":["Mycobacterium Abscessus Pulmonary Disease","Mycobacterium Abscessus Infection","Non-Tuberculous Mycobacterial (NTM) Infections","Non-Tuberculous Mycobacteria Pulmonary Disease"],"enrollment":300,"completionDate":"2031-07"},{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":["Pulmonary Tuberculosis"],"enrollment":315,"completionDate":"2027-08-11"},{"nctId":"NCT07477119","phase":"PHASE4","title":"Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Marco Schiuma","startDate":"2026-03","conditions":["Linezolid","Tuberculosis Multi Drug Resistant Active","Therapeutic Drug Monitoring (TDM)"],"enrollment":150,"completionDate":"2028-04"},{"nctId":"NCT05548426","phase":"PHASE2","title":"Linezolid for Syphilis Pilot Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-09-28","conditions":["Syphilis"],"enrollment":24,"completionDate":"2026-08"},{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":["Osteomyelitis (Refractory)"],"enrollment":280,"completionDate":"2030-12-31"},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":["Endocarditis Infective"],"enrollment":360,"completionDate":"2027-12-30"},{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":["Pulmonary Tuberculosis"],"enrollment":532,"completionDate":"2028-09-29"},{"nctId":"NCT05571722","phase":"PHASE4","title":"Linezolid or Vancomycin Surgical Site Infection Prophylaxis","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-11-12","conditions":["Antibiotic Prophylaxis","General Surgery"],"enrollment":1160,"completionDate":"2029-12-03"},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":["Tuberculosis","Multidrug Resistant Pulmonary Tuberculosis","Rifampicin-resistant Tuberculosis"],"enrollment":60,"completionDate":"2026-09-04"},{"nctId":"NCT07372781","phase":"PHASE2","title":"Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Chest Hospital","startDate":"2026-01-01","conditions":["Monotherapy","Mycobacterium Abscessus Infection"],"enrollment":24,"completionDate":"2026-12-31"},{"nctId":"NCT06590428","phase":"NA","title":"Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2026-03","conditions":["Rifampin-resistant Tuberculosis","Drug-resistant Tuberculosis"],"enrollment":280,"completionDate":"2029-12"},{"nctId":"NCT06441006","phase":"PHASE2,PHASE3","title":"Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-10-03","conditions":["Tuberculosis, Pulmonary","Tuberculosis, Multidrug-Resistant","Tuberculosis, MDR"],"enrollment":400,"completionDate":"2031-08"},{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":["Sepsis","Tuberculosis"],"enrollment":344,"completionDate":"2029-09"},{"nctId":"NCT07301294","phase":"PHASE4","title":"Microbiological Characteristics of Biofilm on Double J Ureteral Stents After Lithotripsy.","status":"NOT_YET_RECRUITING","sponsor":"Menoufia University","startDate":"2026-01-01","conditions":["Double J Stent"],"enrollment":100,"completionDate":"2026-07-01"},{"nctId":"NCT03012360","phase":"PHASE4","title":"Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2018-02-08","conditions":["Mechanical Ventilation Complication","Critical Illness"],"enrollment":103,"completionDate":"2024-07-07"},{"nctId":"NCT05206500","phase":"PHASE4","title":"NextGen - Clinical Implication of Next Generation Sequencing","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-05-17","conditions":["Urinary Tract Infections"],"enrollment":100,"completionDate":"2028-12"},{"nctId":"NCT07268664","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-12-01","conditions":["Rifampicin Resistant Tuberculosis","Pulmonary Tuberculosis","Tuberculosis","Drug-resistant Tuberculosis"],"enrollment":120,"completionDate":"2028-08-31"},{"nctId":"NCT06602245","phase":"","title":"Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis","status":"COMPLETED","sponsor":"Efferon JSC","startDate":"2024-10-21","conditions":["Sepsis","Septic Shock"],"enrollment":30,"completionDate":"2025-04-06"},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":["Tuberculous Meningitis"],"enrollment":330,"completionDate":"2029-09-15"},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":["HIV Infections"],"enrollment":1578,"completionDate":"2020-09-30"},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":["Pulmonary Tuberculosis"],"enrollment":610,"completionDate":"2029-12"},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":["Non-Tuberculous Mycobacterial (NTM) Pneumonia","Mycobacterium Abscessus Infection"],"enrollment":1,"completionDate":"2027-10"},{"nctId":"NCT07230041","phase":"","title":"In Vivo Antibiotics Removal During Hemoadsorption Cartridges and Continuous Renal Replacement Therapy in the Intensive Care Unit","status":"RECRUITING","sponsor":"Niguarda Hospital","startDate":"2025-01-15","conditions":["Septic Shock"],"enrollment":20,"completionDate":"2026-02-15"},{"nctId":"NCT07227779","phase":"PHASE2","title":"B-PaLMZ for TB Meningitis","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-02-15","conditions":["Tuberculous Meningitis"],"enrollment":240,"completionDate":"2030-08-31"},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":["HIV Infections","Tuberculosis"],"enrollment":205,"completionDate":"2025-07-10"},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":["Pulmonary Tuberculosis"],"enrollment":2500,"completionDate":"2027-08-11"},{"nctId":"NCT07204522","phase":"","title":"Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-09-22","conditions":["Febrile Neutropenia"],"enrollment":20,"completionDate":"2027-09-22"},{"nctId":"NCT07198685","phase":"NA","title":"6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":["Treat to Target","Treatment Duration"],"enrollment":52,"completionDate":"2028-09-30"},{"nctId":"NCT07191834","phase":"","title":"A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-30","conditions":["Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis","Type 2 Diabetes Mellitus (T2DM)","Pretomanid"],"enrollment":60,"completionDate":"2027-09-30"},{"nctId":"NCT05369052","phase":"PHASE3","title":"Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)","status":"RECRUITING","sponsor":"MicuRx","startDate":"2022-05-03","conditions":["Diabetic Foot Infection"],"enrollment":865,"completionDate":"2026-06-30"},{"nctId":"NCT02333799","phase":"PHASE3","title":"A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-03","conditions":["Pulmonary Tuberculosis"],"enrollment":109,"completionDate":"2020-08-03"},{"nctId":"NCT06649721","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-11-27","conditions":["Drug-resistant Tuberculosis","Pulmonary Tuberculosis","Rifampin-resistant Tuberculosis"],"enrollment":120,"completionDate":"2027-06-30"},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":["Endovascular Infection","Bone and Joint Infection","Skin and Soft Tissue Infection","Pulmonary Infection","Gastrointestinal Infection","Genitourinary Infection"],"enrollment":94,"completionDate":"2025-02-14"},{"nctId":"NCT07138521","phase":"PHASE4","title":"Optimizing Linezolid Dosing in Patients With Advanced Renal Impairment: a Therapeutic Drug Monitoring-based Evaluation","status":"NOT_YET_RECRUITING","sponsor":"Alexandria University","startDate":"2025-10-15","conditions":["Kidney Disease"],"enrollment":50,"completionDate":"2026-05-15"},{"nctId":"NCT07126639","phase":"NA","title":"A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Pulmonary Hospital","startDate":"2025-09-01","conditions":["Efficacy and Safety"],"enrollment":200,"completionDate":"2028-09-30"},{"nctId":"NCT04310930","phase":"PHASE2,PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":["Pulmonary Disease Due to Mycobacteria (Diagnosis)"],"enrollment":300,"completionDate":"2030-06-30"},{"nctId":"NCT05007821","phase":"PHASE2","title":"Linezolid Dosing Strategies in Drug-Resistant TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-11","conditions":["Tuberculosis, Multidrug-Resistant","Tuberculosis","Tuberculosis, Pulmonary"],"enrollment":138,"completionDate":"2026-03-13"},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":["Acute Bacterial Skin and Skin Structure Infections"],"enrollment":100,"completionDate":"2023-07-06"},{"nctId":"NCT06761131","phase":"","title":"Compare Linezolid-Induced Thrombocytopenia in Patients With Normal Renal Function Versus Impaired Renal Function","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-05-20","conditions":["Thrombocytopaenia","Impaired Renal Function"],"enrollment":60,"completionDate":"2025-06-20"},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":["Endocarditis, Infective"],"enrollment":284,"completionDate":"2028-12-31"},{"nctId":"NCT05069974","phase":"PHASE3","title":"Alternative Antibiotics for Syphilis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2021-10-14","conditions":["Early Latent Syphilis","Primary Syphilis","Secondary Syphilis"],"enrollment":224,"completionDate":"2026-04"},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":["Pulmonary Tuberculosis"],"enrollment":300,"completionDate":"2030-07-31"},{"nctId":"NCT05944458","phase":"PHASE4","title":"Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2023-08-01","conditions":["Linezolid","Antioxidant","Thrombocytopenia","Critical Illness","ICU"],"enrollment":250,"completionDate":"2025-06-01"},{"nctId":"NCT06959667","phase":"","title":"Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-15","conditions":["Methicillin-susceptible S. Aureus (MSSA)","Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA)","Complicated Skin and Soft Tissue,cSSTI"],"enrollment":144,"completionDate":"2025-12-31"},{"nctId":"NCT06921213","phase":"PHASE2","title":"Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis","status":"NOT_YET_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2025-10-01","conditions":["Syphilis, Congenital"],"enrollment":90,"completionDate":"2027-06-30"},{"nctId":"NCT03828201","phase":"PHASE2","title":"Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-06-07","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":220,"completionDate":"2027-05-31"},{"nctId":"NCT00664313","phase":"PHASE1,PHASE2","title":"TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2009-04","conditions":["Multi-drug Resistant Tuberculosis","Extensively Drug Resistant Tuberculosis"],"enrollment":36,"completionDate":"2010-09"},{"nctId":"NCT05081401","phase":"PHASE3","title":"Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2022-05-23","conditions":["Multidrug Resistant Tuberculosis","Rifampicin Resistant Tuberculosis","Pre-XDR-TB"],"enrollment":1050,"completionDate":"2027-12-01"},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":["Pulmonary Tuberculosis","Rifampicin-resistant Tuberculosis"],"enrollment":186,"completionDate":"2026-12-31"},{"nctId":"NCT06058299","phase":"PHASE2","title":"Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Global Alliance for TB Drug Development","startDate":"2023-10-24","conditions":["Pulmonary TB","Pulmonary Tuberculosis","Drug Sensitive Tuberculosis"],"enrollment":309,"completionDate":"2026-06"},{"nctId":"NCT03896685","phase":"PHASE3","title":"Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2020-04-06","conditions":["Tuberculosis, Multidrug-Resistant","Tuberculosis","Pulmonary Tuberculoses","Mycobacterial Infections","Bacterial Infections","Gram-Positive Bacterial Infections"],"enrollment":323,"completionDate":"2024-12-31"},{"nctId":"NCT02754765","phase":"PHASE3","title":"Evaluating Newly Approved Drugs for Multidrug-resistant TB","status":"COMPLETED","sponsor":"Médecins Sans Frontières, France","startDate":"2016-12","conditions":["Tuberculosis, Multidrug-Resistant","Infection, Bacterial","Pulmonary Tuberculoses"],"enrollment":754,"completionDate":"2023-06"},{"nctId":"NCT06811025","phase":"PHASE1,PHASE2","title":"Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Chest Hospital","startDate":"2024-02-01","conditions":["Tuberculosis","Meningitis"],"enrollment":24,"completionDate":"2025-12-31"},{"nctId":"NCT06811012","phase":"PHASE1,PHASE2","title":"Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Chest Hospital","startDate":"2024-01-31","conditions":["Tuberculosis","Bone","Joint"],"enrollment":24,"completionDate":"2025-12-31"},{"nctId":"NCT02365623","phase":"PHASE2","title":"An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2015-02-18","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":6,"completionDate":"2018-11-08"},{"nctId":"NCT05534750","phase":"PHASE2","title":"Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-20","conditions":["Tuberculosis","Multidrug Resistant Tuberculosis"],"enrollment":60,"completionDate":"2026-05"},{"nctId":"NCT03583333","phase":"PHASE3","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-18","conditions":["Hospital-Acquired Bacterial Pneumonia","Ventilator-Associated Bacterial Pneumonia"],"enrollment":274,"completionDate":"2022-07-12"},{"nctId":"NCT05764876","phase":"PHASE3","title":"Repurposing Clinically Approved Drugs for Yaws with an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2023-03-14","conditions":["Yaws","Cutaneous Ulcer"],"enrollment":465,"completionDate":"2024-12-01"},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":["Cystectomy","Bladder Cancer Requiring Cystectomy","Postoperative Infections","Antibiotic Prophylaxis","Ileal Conduit"],"enrollment":248,"completionDate":"2027-01"},{"nctId":"NCT02619994","phase":"PHASE2","title":"Treatment Shortening of MDR-TB Using Existing and New Drugs","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":214,"completionDate":"2021-06"},{"nctId":"NCT06729619","phase":"","title":"Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xueyan Cui","startDate":"2024-06-03","conditions":["Intracranial Infection","Central Infection"],"enrollment":200,"completionDate":"2027-12-31"},{"nctId":"NCT03220074","phase":"PHASE4","title":"Linezolid for Treatment of Nontuberculous Mycobacterial Diseases","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-12-15","conditions":["Non-tuberculous Mycobacterial Infections"],"enrollment":40,"completionDate":"2022-06-15"},{"nctId":"NCT04717908","phase":"NA","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2021-01-20","conditions":["Multidrug Resistant Tuberculosis"],"enrollment":89,"completionDate":"2024-06-22"},{"nctId":"NCT03867136","phase":"PHASE4","title":"Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2020-06-01","conditions":["Multidrug Resistant Tuberculosis"],"enrollment":354,"completionDate":"2024-08-10"},{"nctId":"NCT06674291","phase":"","title":"Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)","status":"NOT_YET_RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2024-11-30","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":222,"completionDate":"2028-12-31"},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm"],"enrollment":100,"completionDate":"2023-10-06"},{"nctId":"NCT02269319","phase":"PHASE2","title":"MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"MicuRx","startDate":"2015-02","conditions":["Bacterial Infections"],"enrollment":120,"completionDate":"2015-09"},{"nctId":"NCT04021121","phase":"PHASE2","title":"Adjunctive Linezolid for the Treatment of Tuberculous Meningitis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-05-05","conditions":["Tuberculosis, Meningeal"],"enrollment":40,"completionDate":"2023-12-04"},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":["Tuberculosis","Pre-XDR-TB","Extensively Drug-Resistant Tuberculosis","Multi Drug Resistant Tuberculosis","Rifampicin Resistant Tuberculosis"],"enrollment":402,"completionDate":"2024-04-15"},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":290,"completionDate":"2025-06"},{"nctId":"NCT06476210","phase":"PHASE4","title":"The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)","status":"RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2024-06","conditions":["Pulmonary Tuberculosis"],"enrollment":45,"completionDate":"2026-06"},{"nctId":"NCT06444802","phase":"PHASE3","title":"Model-informed Precision Dosing for Linezolid","status":"NOT_YET_RECRUITING","sponsor":"University of Hamburg-Eppendorf","startDate":"2024-09-01","conditions":["Gram-Positive Bacterial Infections"],"enrollment":28,"completionDate":"2026-06-30"},{"nctId":"NCT03942354","phase":"","title":"Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2019-09-01","conditions":["Multidrug Resistant Tuberculosis"],"enrollment":137,"completionDate":"2022-05-10"},{"nctId":"NCT02589782","phase":"PHASE2,PHASE3","title":"Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2017-01","conditions":["Tuberculosis, Multidrug-Resistant","Extensively Drug-Resistant Tuberculosis","Tuberculosis, Pulmonary"],"enrollment":552,"completionDate":"2022-08-05"},{"nctId":"NCT04207112","phase":"PHASE2,PHASE3","title":"Economic Evaluation of New MDR TB Regimens","status":"COMPLETED","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2020-10-20","conditions":["Multi-drug Resistant Tuberculosis","Extensively Drug-Resistant Tuberculosis","Pulmonary Tuberculoses"],"enrollment":73,"completionDate":"2022-08-25"},{"nctId":"NCT05381194","phase":"PHASE4","title":"BPaL(M) Regimen for the Treatment of MDR/RR-TB","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-12-13","conditions":["Multidrug- and Rifampicin-resistant Tuberculosis"],"enrollment":80,"completionDate":"2027-12"},{"nctId":"NCT06291181","phase":"NA","title":"Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-01-01","conditions":["Staphylococcus Aureus"],"enrollment":265,"completionDate":"2023-06-30"},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":["Tuberculous Meningitis"],"enrollment":768,"completionDate":"2026-04"},{"nctId":"NCT05040126","phase":"PHASE3","title":"Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2021-10-07","conditions":["Pre-Extensively Drug-Resistant Pulmonary TB","Treatment Intolerant Multidrug-Resistant Pulmonary TB","Non-responsive Multidrug-Resistant Pulmonary TB"],"enrollment":400,"completionDate":"2024-12-31"},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":["Endocarditis"],"enrollment":20,"completionDate":"2024-10"},{"nctId":"NCT06126263","phase":"","title":"Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections","status":"UNKNOWN","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2023-01-01","conditions":["Streptococcal Sepsis","Invasive Group A Beta-Haemolytic Streptococcal Disease","Necrotizing Soft Tissue Infection","Infection, Bloodstream","Infection, Bacterial","Streptococcal Toxic Shock Syndrome"],"enrollment":1000,"completionDate":"2024-06-30"},{"nctId":"NCT00501150","phase":"NA","title":"Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-09","conditions":["Gram-positive Bacterial Infections","Staphylococcal Infections"],"enrollment":211,"completionDate":"2007-06"},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":["Tuberculosis, Meningeal","Linezolid"],"enrollment":36,"completionDate":"2023-07-20"},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":205,"completionDate":"2022-12-19"},{"nctId":"NCT03474198","phase":"PHASE2,PHASE3","title":"Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-03-21","conditions":["Tuberculosis, Pulmonary"],"enrollment":675,"completionDate":"2022-01-20"},{"nctId":"NCT05293132","phase":"PHASE2,PHASE3","title":"Effect of Montelukast Versus Co Enzyme in Sepsis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-01","conditions":["Sepsis"],"enrollment":90,"completionDate":"2023-06-01"},{"nctId":"NCT05944445","phase":"","title":"The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT","status":"UNKNOWN","sponsor":"Helwan University","startDate":"2023-07-13","conditions":["Thrombocytopenia; Drugs"],"enrollment":310,"completionDate":"2024-08"},{"nctId":"NCT03086486","phase":"PHASE3","title":"Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2017-11-21","conditions":["Tuberculosis, Pulmonary","Tuberculosis, Multidrug-Resistant","Tuberculosis, MDR","Tuberculosis","Extensively Drug-Resistant Tuberculosis","Pre-XDR-TB","XDR-TB"],"enrollment":181,"completionDate":"2022-02-08"},{"nctId":"NCT01734694","phase":"PHASE4","title":"Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2011-10","conditions":["Health Care Associated Pneumonia","Osteomyelitis/Septic Arthritis","Endocarditis","Bacteremia","Acute Bacterial Skin and Skin Structure Infections"],"enrollment":100,"completionDate":"2012-09"},{"nctId":"NCT05813951","phase":"NA","title":"Efficacy and Safety of Continuous Versus Intermittent Linezolid Infusion in Critically Ill Patients With Septic Shock","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-12-02","conditions":["Treatment Efficacy"],"enrollment":140,"completionDate":"2023-12-02"},{"nctId":"NCT05801484","phase":"NA","title":"Pharmacokinetics and Pharmacodynamics of Linezolid Continuous and Intermittent Administration","status":"UNKNOWN","sponsor":"Cluj Municipal Clinical Hospital","startDate":"2022-07-01","conditions":["Side-effect of Antibiotic","Efficacy","Pharmacokinetics","Critical Illness","Intensive Care Unit ICU"],"enrollment":60,"completionDate":"2024-07-30"},{"nctId":"NCT02660554","phase":"NA","title":"Trial of MRSA Polymerase Chain Reaction for Pneumonia","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-01","conditions":["Pneumonia","Methicillin-Resistant Staphylococcus Aureus"],"enrollment":45,"completionDate":"2019-05-03"},{"nctId":"NCT05306223","phase":"PHASE4","title":"A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2022-05-10","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":212,"completionDate":"2025-08-08"},{"nctId":"NCT03747497","phase":"PHASE2","title":"Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"MicuRx","startDate":"2018-11-15","conditions":["Skin Diseases, Bacterial","Gram-Positive Bacterial Infections"],"enrollment":196,"completionDate":"2019-03-26"},{"nctId":"NCT03830671","phase":"PHASE4","title":"The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB","status":"COMPLETED","sponsor":"Beijing Chest Hospital","startDate":"2019-03-08","conditions":["Multi-drug Resistant Tuberculosis"],"enrollment":515,"completionDate":"2022-06-08"},{"nctId":"NCT05494957","phase":"PHASE4","title":"Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-08-05","conditions":["Nontuberculous Mycobacterial Lung Disease"],"enrollment":40,"completionDate":"2025-08-05"},{"nctId":"NCT05354635","phase":"","title":"Therapeutic Follow-up of Antibiotics in Pediatric Intensive Care","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2022-06","conditions":["Intensive Care Units, Pediatric"],"enrollment":280,"completionDate":"2025-06"},{"nctId":"NCT05339802","phase":"PHASE2","title":"A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-02-16","conditions":["Skin Infection"],"enrollment":90,"completionDate":"2023-12"},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":["Other Infectious Diseases"],"enrollment":100,"completionDate":"2022-02-16"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Granule, Injection, Powder, Suspension","formulations":[{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","productName":"Linezolid"},{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","productName":"Zyvox"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Linezolid"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Zyvox"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Linezolid"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"linezolid"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Linezolid"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Zyvox"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Linezolid"},{"form":"SUSPENSION","route":"ORAL","productName":"Zyvox"},{"form":"SUSPENSION","route":"ORAL","productName":"Linezolid"},{"form":"TABLET","route":"ORAL","productName":"Linezolid"},{"form":"TABLET","route":"ORAL","productName":"linezolid"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Linezolid"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Zyvox"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148664","MMSL":"229070","NDDF":"008223","UNII":"ISQ9I6J12J","VUID":"4021218","CHEBI":"CHEBI:63607","VANDF":"4021218","INN_ID":"7584","RXNORM":"190376","UMLSCUI":"C0663241","chemblId":"CHEMBL126","ChEMBL_ID":"CHEMBL126","KEGG_DRUG":"D00947","DRUGBANK_ID":"DB00601","PDB_CHEM_ID":" ZLD","PUBCHEM_CID":"441401","SNOMEDCT_US":"125695009","IUPHAR_LIGAND_ID":"10827","MESH_DESCRIPTOR_UI":"D000069349"},"formularyStatus":[],"originalProduct":{"form":"GRANULE, FOR SUSPENSION","route":"ORAL","company":"Pharmacia & Upjohn Company LLC","brandName":"Zyvox","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"2000-","companyName":"Pharmacia And Upjohn","relationship":"Original Developer"},{"period":"present","companyName":"Pfizer","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.5 hours","clearance":"1.8 mL/min/kg","bioavailability":"99%","fractionUnbound":"0.69%","volumeOfDistribution":"0.58 L/kg"},"publicationCount":9548,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"J01XX08","allCodes":["J01XX08"]},"biosimilarFilings":[],"originalDeveloper":"Pharmacia And Upjohn","recentPublications":[{"date":"2026 Mar 16","pmid":"41901773","title":"Whole-Genome Sequencing and Phenotypic Drug Susceptibility Testing of Bedaquilin, Delamanid, Pretomanid, and Linezolid in Drug-Resistant Mycobacterium tuberculosis from a Single Institute in South Korea.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2026 Mar 6","pmid":"41901277","title":"Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 20","pmid":"41894901","title":"Linezolid-associated adverse events and outcomes in the treatment of multidrug/rifampicin-resistant tuberculosis: A systematic review and meta-analysis of randomized controlled trials.","journal":"Journal of infection and public health"},{"date":"2026 Jan 1","pmid":"41894629","title":"Investigation of In vitro Efficacy of New Generation Drugs Tedizolid and Omadacycline against Nontuberculous Mycobacteria.","journal":"International journal of mycobacteriology"},{"date":"2026 Jan 1","pmid":"41894624","title":"Prevalence of Bedaquiline Resistance among Drug Resistant - Tuberculosis Cases at a Tertiary Healthcare Setting in Metropolitan City of Maharashtra, India.","journal":"International journal of mycobacteriology"}],"companionDiagnostics":[],"genericManufacturers":24,"_genericFilersChecked":true,"genericManufacturerList":["Alembic","Alkem Labs Ltd","Amneal Pharms","Caplin","Chartwell Rx","Eugia Pharma","Fresenius Kabi Usa","Gate Pharms","Glenmark Speclt","Hetero Labs","Hetero Labs Ltd V","Hikma","Hospira","Hq Spclt Pharma","Macleods Pharms Ltd","Nang Kuang Pharm Co","Novel Labs Inc","Pharmobedient","Rising","Sagent Pharms Inc","Sandoz","Teva Pharms","Teva Pharms Usa","Zydus Pharms"],"status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"2000","enrichmentLevel":4,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-12-21T00:00:00.000Z","mah":"HETERO LABS LTD V","brand_name_local":null,"application_number":"ANDA204239"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-06-27T00:00:00.000Z","mah":"EUGIA PHARMA","brand_name_local":null,"application_number":"ANDA206917"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-01-18T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"NDA206473"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-08-22T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA206454"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-10-23T00:00:00.000Z","mah":"NANG KUANG PHARM CO","brand_name_local":null,"application_number":"ANDA207354"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"712.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"712.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"712.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"712.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"712.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":13,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:40.314787+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}